Improved adeno-associated virus binding protein, method for producing the protein, and adeno-associated virus adsorbent using the protein
By substituting specific amino acid residues in AAV binding proteins, the stability to heat, acid and alkali is improved, and the use of AAV adsorbents is used to solve the problem of low purification efficiency of AAV carriers, and more efficient AAV vector application.
Patent Information
- Application Number
- CN202080081905.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-09-30
- Filing Date
- 2020-11-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-11-24
AI Technical Summary
The existing AAV-binding proteins have low stability to heat, acid and alkali, which affects their use in industrial applications.
By substituting specific amino acid residues of the AAV-binding protein to improve its stability to heat, acid and base, an improved AAV-binding protein was prepared, and the AAV adsorbent was used to improve the purification efficiency of AAV.
It improves the thermal, acid and alkali stability of AAV-binding proteins, enhances the purification ability of AAV, and improves the application efficiency of AAV vectors.
Smart Images

Figure CN114746552B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a protein that binds to adeno-associated virus (AAV), and more specifically, to an improved AAV-binding protein that is more stable to heat, acid, and alkali than a wild type, a method for producing the protein, and an AAV adsorbent using the protein. Background Art
[0002] AAV is a non-enveloped virus classified in the Parvoviridae family and the Dependovirus genus. The AAV capsid particle is composed of about 60 protein molecules, with the ratio of three proteins (VP1, VP2, and VP3) being 1:1:10, and has a regular icosahedral shape with a diameter of 20 to 30 nm.
[0003] AAV in nature lacks autonomous proliferation capabilities, and replication depends on helper viruses such as adenovirus and herpes virus. When the helper virus is present, the AAV genome is replicated in the host cell to form complete AAV particles containing the AAV genome, and the AAV particles are released from the host cell. On the other hand, in the absence of the helper virus, the AAV genome becomes maintained as an episome or integrated into the host chromosome (latent state).
[0004] AAV can infect cells of many species including humans, and can also infect non-dividing cells that have stopped differentiation, such as blood cells, muscles, and nerve cells. Since it is not pathogenic to humans and there is no need to worry about side effects, and the virus particles are physically and chemically stable, its value as a gene introduction vector for the treatment of congenital genetic diseases has attracted much attention.
[0005] The production of genetically recombinant AAV vectors (hereinafter also simply referred to as AAV vectors) is usually carried out as follows: nucleic acids encoding elements necessary for the formation of AAV particles are introduced into cells to produce cells with the ability to produce AAV (hereinafter also referred to as AAV-producing cells), and the cells are cultured to express the elements necessary for the formation of AAV particles. Usually, the following three plasmids are introduced into cells to produce AAV: a plasmid (vector plasmid) for supplying a recombinant AAV genome, wherein the recombinant AAV genome is obtained by retaining ITR (Inverted Terminal Repeat, reverse terminal repeat) sequences at both ends and carrying a polynucleotide encoding the protein to be expressed; a plasmid (packaging plasmid) for supplying Rep protein and capsid protein (capsid constituting proteins VP1, VP2 and VP3); a plasmid (helper plasmid) for supplying only elements necessary for the formation of AAV particles among adenovirus-derived elements. As other methods, the following methods can also be used for production: a method using cells obtained by pre-introducing elements necessary for the formation of AAV particles into host cells; a method using insect cells (Sf9 cells, etc.).
[0006] In gene introduction using AAV vectors, it is necessary for AAV vectors to invade cells. It is known that in the first step of AAV invasion into cells, it binds to the cell surface and receptors, and this binding involves heparan sulfate, integrin and receptors on the cell surface such as FGF (Fibro blast growth factor) receptors and HGF (hepatocyte growth factor) receptors. Generally, it is known that the receptors bound to when invading cells are different depending on the serotype of the AAV vector.
[0007] In addition, a receptor (AAVR) called KIAA0319L has been reported as a universal receptor (non-patent literature 1). It is reported that the AAVR is composed of 5 extracellular region domains, a transmembrane region, and an intracellular region, and the important binding to AAV is mainly the domain 2 (PKD2) of the extracellular region (non-patent literature 2). AAVR can bind to the AAV vector and can therefore become a ligand for adsorbing AAV. However, AAVR is a protein derived from humans, so there is a problem of low stability when used industrially.
[0008] Prior art literature
[0009] Non-patent literature
[0010] Non-patent document 1: Pillay S., et.al., Nature, 530, 108-112, 2016
[0011] Non-patent literature 2: Zhang.R., et.al., Nat.Microbiol., 4, 675-682, 2019 Summary of the invention
[0012] Problem that the invention aims to solve
[0013] The present invention aims to provide an improved AAV-binding protein having improved stability, particularly with respect to heat, acid, and alkali, a method for producing the protein, and an AAV adsorbent using the protein.
[0014] Solutions for solving problems
[0015] The present inventors conducted intensive research to solve the above-mentioned problems, and as a result, identified the amino acid residues in the AAV binding protein that are involved in improving stability, and found that mutants obtained by replacing the amino acid residues with other amino acid residues have excellent stability to heat, acid and alkali, thus completing the present invention.
[0016] That is, the present invention includes the following aspects described in [1] to
[10] :
[0017] [1] An AAV-binding protein selected from any of the following (i) to (iii):
[0018] (i) an AAV-binding protein comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence of SEQ ID NO: 1, wherein at least one of the following amino acid substitutions (1) to (137) is made in the amino acid residues from positions 312 to 500;
[0019] (1) Glycine at position 390 of SEQ ID NO: 1 was substituted with serine
[0020] (2) Isoleucine at position 319 of SEQ ID NO: 1 was substituted with phenylalanine
[0021] (3) Leucine at position 321 of SEQ ID NO: 1 was substituted with proline
[0022] (4) Proline at position 322 of SEQ ID NO: 1 was substituted with leucine
[0023] (5) Asparagine at position 324 of SEQ ID NO: 1 is substituted with aspartic acid or serine
[0024] (6) Glutamine at position 327 of sequence number 1 was replaced by arginine
[0025] (7) Asparagine at position 329 of SEQ ID NO: 1 is substituted with aspartic acid or tyrosine
[0026] (8) Alanine at position 330 of SEQ ID NO: 1 was substituted with glycine
[0027] (9) Tyrosine at position 331 of SEQ ID NO: 1 was substituted with cysteine
[0028] (10) Valine at position 332 of sequence number 1 was replaced by glutamine
[0029] (11) Leucine at position 333 of SEQ ID NO: 1 is substituted with valine or proline
[0030] (12) Glutamine at position 334 of sequence number 1 was replaced by arginine
[0031] (13) Proline at position 337 of SEQ ID NO: 1 was substituted with leucine
[0032] (14) Lysine at position 338 of SEQ ID NO: 1 is substituted with arginine or glutamic acid
[0033] (15) Glutamic acid at position 340 of sequence number 1 was substituted with glycine
[0034] (16) The threonine at position 341 of SEQ ID NO: 1 was substituted with alanine
[0035] (17) The tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, histidine or asparagine
[0036] (18) Threonine at position 343 of SEQ ID NO: 1 was substituted with methionine
[0037] (19) Tyrosine at position 344 of SEQ ID NO: 1 was substituted with histidine
[0038] (20) Aspartic acid at position 345 of sequence number 1 was substituted with asparagine
[0039] (21) The tryptophan at position 346 of SEQ ID NO: 1 is substituted with leucine or arginine
[0040] (22) Glutamine at position 347 of SEQ ID NO: 1 is substituted with leucine or proline
[0041] (23) Leucine at position 348 of SEQ ID NO: 1 was substituted with proline
[0042] (24) Isoleucine at position 349 of SEQ ID NO: 1 was substituted with threonine
[0043] (25) Threonine at position 350 of SEQ ID NO: 1 was substituted with methionine
[0044] (26) The histidine at position 351 of SEQ ID NO: 1 was substituted with leucine
[0045] (27) Proline at position 352 of SEQ ID NO: 1 was substituted with leucine
[0046] (28) Arginine at position 353 of SEQ ID NO: 1 was substituted with cysteine
[0047] (29) Aspartic acid at position 354 of SEQ ID NO: 1 was substituted with glycine
[0048] (30) The tyrosine at position 355 of sequence number 1 is replaced by histidine, asparagine or cysteine. (31) The serine at position 356 of sequence number 1 is replaced by cysteine.
[0049] (32) Glycine at position 357 of SEQ ID NO: 1 was substituted with cysteine
[0050] (33) The histidine at position 363 of SEQ ID NO: 1 is substituted with arginine or leucine
[0051] (34) Serine at position 364 of SEQ ID NO: 1 was substituted with proline
[0052] (35) Glutamine at position 365 of sequence number 1 was replaced by arginine
[0053] (36) Isoleucine at position 366 of SEQ ID NO: 1 was substituted with threonine
[0054] (37) Leucine at position 367 of SEQ ID NO: 1 was substituted with proline
[0055] (38) Lysine at position 368 of SEQ ID NO: 1 was substituted with arginine
[0056] (39) Leucine at position 369 of SEQ ID NO: 1 is substituted with glutamine or proline
[0057] (40) The serine at position 370 of SEQ ID NO: 1 was substituted with alanine
[0058] (41) Lysine at position 371 of SEQ ID NO: 1 was substituted with glutamic acid
[0059] (42) Threonine at position 373 of SEQ ID NO: 1 was substituted with alanine
[0060] (43) Leucine at position 376 of SEQ ID NO: 1 was substituted with proline
[0061] (44) Tyrosine at position 377 of SEQ ID NO: 1 was substituted with cysteine
[0062] (45) Phenylalanine at position 379 of SEQ ID NO: 1 was substituted with serine
[0063] (46) The valine at position 381 of sequence number 1 was substituted with alanine
[0064] (47) Glutamic acid at position 384 of sequence number 1 was substituted with glycine
[0065] (48) Asparagine at position 387 of SEQ ID NO: 1 was substituted with serine
[0066] (49) The histidine at position 389 of SEQ ID NO: 1 is substituted with glutamine, leucine or arginine
[0067] (50) Glutamic acid at position 391 of sequence number 1 was substituted with lysine
[0068] (51) Tyrosine at position 393 of SEQ ID NO: 1 was substituted with cysteine
[0069] (52) The valine at position 396 of sequence number 1 was substituted with alanine
[0070] (53) Lysine at position 399 of SEQ ID NO: 1 is substituted with glutamic acid or arginine
[0071] (54) Arginine at position 406 of sequence number 1 was substituted with serine
[0072] (55) The valine at position 412 of sequence number 1 was substituted with alanine
[0073] (56) Glutamine at position 415 of sequence number 1 was replaced by leucine
[0074] (57) Phenylalanine at position 416 of SEQ ID NO: 1 was substituted with serine
[0075] (58) Glutamine at position 441 of sequence number 1 was replaced by leucine
[0076] (59) Tyrosine at position 442 of sequence number 1 was substituted with phenylalanine
[0077] (60) Lysine at position 448 of SEQ ID NO: 1 was substituted with arginine
[0078] (61) Glutamic acid at position 453 of sequence number 1 was substituted with glycine
[0079] (62) Lysine at position 455 of SEQ ID NO: 1 was substituted with arginine
[0080] (63) Glutamic acid at position 458 of sequence number 1 was substituted with glycine
[0081] (64) Alanine at position 461 of SEQ ID NO: 1 was substituted with serine
[0082] (65) The serine at position 476 of sequence number 1 was substituted with arginine
[0083] (66) Leucine at position 477 of SEQ ID NO: 1 was substituted with proline
[0084] (67) Asparagine at position 487 of sequence number 1 was substituted with aspartic acid
[0085] (68) Asparagine at position 492 of sequence number 1 was substituted with aspartic acid
[0086] (69) Isoleucine at position 319 of SEQ ID NO: 1 is substituted with asparagine or serine
[0087] (70) Threonine at position 320 of SEQ ID NO: 1 was substituted with isoleucine
[0088] (71) Lysine at position 323 of SEQ ID NO: 1 was substituted with glutamic acid
[0089] (72) Leucine at position 328 of SEQ ID NO: 1 is substituted with glutamine or proline
[0090] (73) The tyrosine at position 331 of sequence number 1 was replaced by histidine
[0091] (74) The valine at position 332 of sequence number 1 is substituted with alanine or glutamic acid
[0092] (75) Proline at position 336 of SEQ ID NO: 1 was replaced by glutamine
[0093] (76) Proline at position 337 of SEQ ID NO: 1 was replaced by glutamine
[0094] (77) Lysine at position 338 of SEQ ID NO: 1 was substituted with asparagine
[0095] (78) Tyrosine at position 342 of sequence number 1 was replaced by arginine
[0096] (79) Threonine at position 350 of SEQ ID NO: 1 was substituted with serine
[0097] (80) Isoleucine at position 366 of SEQ ID NO: 1 was substituted with phenylalanine
[0098] (81) The valine at position 383 of SEQ ID NO: 1 was substituted with alanine
[0099] (82) Glutamine at position 386 of sequence number 1 was replaced by arginine
[0100] (83) The histidine at position 389 of SEQ ID NO: 1 was substituted with aspartic acid
[0101] (84) Glycine at position 392 of SEQ ID NO: 1 was substituted with cysteine
[0102] (85) The valine at position 394 of sequence number 1 was substituted with alanine
[0103] (86) Isoleucine at position 409 of SEQ ID NO: 1 was substituted with valine
[0104] (87) Serine at position 476 of SEQ ID NO: 1 was substituted with glycine
[0105] (88) Threonine at position 490 of SEQ ID NO: 1 was substituted with serine
[0106] (89) Serine at position 312 of SEQ ID NO: 1 was substituted with proline
[0107] (90) Alanine at position 313 of SEQ ID NO: 1 was substituted with serine
[0108] (91) Valine at position 317 of sequence number 1 was substituted with aspartic acid
[0109] (92) Glutamine at position 318 of sequence number 1 was replaced by proline
[0110] (93) The threonine at position 320 of SEQ ID NO: 1 was substituted with alanine
[0111] (94) Lysine at position 323 of SEQ ID NO: 1 was substituted with arginine
[0112] (95) The valine at position 326 of SEQ ID NO: 1 is substituted with alanine or glutamic acid
[0113] (96) Glutamine at position 327 of SEQ ID NO: 1 is substituted with histidine or leucine
[0114] (97) Asparagine at position 329 of SEQ ID NO: 1 is substituted with histidine or isoleucine
[0115] (98) The valine at position 332 of sequence number 1 was substituted with alanine
[0116] (99) Glutamic acid at position 335 of SEQ ID NO: 1 is substituted with glycine or valine
[0117] (100) The glutamic acid at position 340 of sequence number 1 was replaced by valine
[0118] (101) Threonine at position 341 of sequence number 1 was substituted with proline
[0119] (102) Threonine at position 343 of sequence number 1 was substituted with serine
[0120] (103) The tyrosine at position 344 of sequence number 1 was replaced by phenylalanine
[0121] (104) The tryptophan at position 346 of SEQ ID NO: 1 was substituted with cysteine
[0122] (105) The methionine at position 359 of sequence number 1 was substituted with leucine
[0123] (106) Glutamic acid at position 360 of sequence number 1 is substituted with lysine or valine
[0124] (107) Glycine at position 361 of SEQ ID NO: 1 was substituted with cysteine
[0125] (108) Lysine at position 362 of SEQ ID NO: 1 is substituted with glutamic acid, asparagine or glycine
[0126] (109) Serine at position 364 of SEQ ID NO: 1 was substituted with leucine
[0127] (110) Lysine at position 371 of SEQ ID NO: 1 is substituted with asparagine or aspartic acid
[0128] (111) Leucine at position 372 of SEQ ID NO: 1 is substituted with proline or glutamine
[0129] (112) Proline at position 374 of SEQ ID NO: 1 was substituted with leucine
[0130] (113) Glutamic acid at position 378 of SEQ ID NO: 1 is substituted with glycine or valine
[0131] (114) The phenylalanine at position 379 of SEQ ID NO: 1 is substituted with tyrosine or cysteine
[0132] (115) Lysine at position 380 of SEQ ID NO: 1 was substituted with glutamic acid
[0133] (116) The valine at position 381 of sequence number 1 was substituted with aspartic acid
[0134] (117) Isoleucine at position 382 of SEQ ID NO: 1 was substituted with valine
[0135] (118) Glutamic acid at position 384 of sequence number 1 was substituted with valine
[0136] (119) The valine at position 394 of SEQ ID NO: 1 is substituted with aspartic acid or isoleucine
[0137] (120) Asparagine at position 395 of SEQ ID NO: 1 was substituted with serine
[0138] (121) Threonine at position 397 of SEQ ID NO: 1 was substituted with serine
[0139] (122) Glutamic acid at position 401 of sequence number 1 was substituted with valine
[0140] (123) Arginine at position 403 of SEQ ID NO: 1 was substituted with histidine
[0141] (124) Arginine at position 406 of sequence number 1 was replaced by histidine
[0142] (125) Glutamine at position 415 of sequence number 1 was replaced by arginine
[0143] (126) The threonine at position 426 of SEQ ID NO: 1 was substituted with alanine
[0144] (127) Glutamine at position 432 of SEQ ID NO: 1 is substituted with leucine or arginine
[0145] (128) Glutamine at position 441 of sequence number 1 was replaced by arginine
[0146] (129) The histidine at position 443 of SEQ ID NO: 1 was substituted with leucine
[0147] (130) Lysine at position 448 of SEQ ID NO: 1 was substituted with glutamic acid
[0148] (131) Isoleucine at position 456 of SEQ ID NO: 1 was substituted with valine
[0149] (132) Aspartic acid at position 483 of sequence number 1 was substituted with asparagine
[0150] (133) Serine at position 488 of SEQ ID NO: 1 was substituted with leucine
[0151] (134) The valine at position 499 of SEQ ID NO: 1 is substituted with glutamic acid or isoleucine.
[0152] (ii) an AAV binding protein comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, wherein at least one of the amino acid substitutions (1) to (134) has occurred in the amino acid residues from position 312 to position 500, and further, in addition to the amino acid substitutions shown in (1) to (134), any one or more of the substitutions, deletions, insertions and additions of one or more amino acid residues at one or more positions has occurred, and has AAV binding activity.
[0153] (iii) An AAV binding protein having AAV binding activity comprising the following amino acid sequence, wherein the amino acid sequence has an overall homology of more than 70% with respect to the amino acid sequence in which at least one of the amino acids (1) to (134) is substituted in the amino acid sequence from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and the at least one amino acid substitution remains.
[0154] [2] The AAV-binding protein according to [1], which is selected from any of the following (iv) to (vi):
[0155] (iv) an AAV-binding protein comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence of SEQ ID NO: 1, wherein at least the following amino acid substitution (1) has occurred in the amino acid residues from positions 312 to 500;
[0156] (1) Glycine at position 390 of SEQ ID NO: 1 was substituted with serine
[0157] (v) an AAV-binding protein comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, wherein at least the amino acid substitution of (1) has occurred among the amino acid residues at positions 312 to 500, and further, in addition to the amino acid substitution shown in (1), any one or more of substitutions, deletions, insertions and additions of one or more amino acid residues at one or more positions have occurred, and having AAV-binding activity.
[0158] (vi) An AAV binding protein having AAV binding activity comprising the following amino acid sequence, wherein the amino acid sequence has a homology of 70% or more to the amino acid sequence as a whole in which at least the amino acid substitution of (1) has occurred in the amino acid sequence from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and the amino acid substitution of (1) remains.
[0159] [3] The AAV-binding protein according to [2], wherein at least any of the following amino acid substitutions (A) to (K) is produced;
[0160] (A) Glycine at position 390 of SEQ ID NO: 1 is substituted with serine, and tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine
[0161] (B) Glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and serine at position 476 of SEQ ID NO: 1 is substituted with arginine
[0162] (C) Glycine at position 390 of SEQ ID NO: 1 is substituted with serine, isoleucine at position 319 of SEQ ID NO: 1 is substituted with phenylalanine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and serine at position 476 of SEQ ID NO: 1 is substituted with arginine
[0163] (D) Glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, serine at position 476 of SEQ ID NO: 1 is substituted with arginine, and asparagine at position 487 of SEQ ID NO: 1 is substituted with aspartic acid
[0164] (E) Glycine at position 390 of sequence number 1 is substituted with serine, isoleucine at position 319 of sequence number 1 is substituted with phenylalanine, lysine at position 323 of sequence number 1 is substituted with glutamic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, and serine at position 476 of sequence number 1 is substituted with arginine
[0165] (F) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid
[0166] (G) glycine at position 390 of sequence number 1 is substituted with serine, asparagine at position 324 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid
[0167] (H) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid
[0168] (I) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, asparagine at position 324 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid
[0169] (J) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid
[0170] (K) The glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with serine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 381 of sequence number 1 is substituted with alanine, the isoleucine at position 382 of sequence number 1 is substituted with valine, the glycine at position 390 of sequence number 1 is substituted with serine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, and the asparagine at position 487 of sequence number 1 is substituted with aspartic acid.
[0171] [4] The AAV-binding protein according to [3], which is selected from any of the following (vii) to (ix):
[0172] (vii) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence of any of SEQ ID NOs: 18, 32, 34, 38, 42, 46, 53, 55, 59, 63, 69 and 76;
[0173] (viii) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence of any of SEQ ID NOs: 18, 32, 34, 38, 42, 46, 53, 55, 59, 63, 69 and 76, wherein among the amino acid residues at positions 25 to 213, in addition to the amino acid substitutions in the amino acid sequence, at least one or more of substitutions, deletions, insertions and additions of one or more amino acid residues at one or more positions are further present, and has AAV-binding activity;
[0174] (ix) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence recorded in any of SEQ ID NOs: 18, 32, 34, 38, 42, 46, 53, 55, 59, 63, 69 and 76, wherein the AAV-binding protein has 70% or more homology with the amino acid sequence at positions 25 to 213, has amino acid substitutions contained in the amino acid sequence, and has AAV-binding activity.
[0175] [5] A polynucleotide encoding the AAV-binding protein described in any one of [1] to [4].
[0176] [6] An expression vector comprising the polynucleotide described in [5].
[0177] [7] A transformant obtained by transforming a host with the expression vector described in [6].
[0178] [8] The transformant according to [7], wherein the host is Escherichia coli.
[0179] [9] A method for producing an AAV binding protein, comprising: a step of expressing the AAV binding protein by culturing the transformant described in [7] or [8]; and a step of recovering the expressed AAV binding protein from the obtained culture.
[0180]
[10] An AAV adsorbent comprising an insoluble carrier and the AAV-binding protein according to any one of [1] to [3] immobilized on the carrier.
[0181]
[11] A column comprising the AAV adsorbent described in
[10] .
[0182]
[12] A method for purifying AAV, comprising: adding a solution containing AAV to the column described in
[11] to allow the adsorbent to adsorb the AAV; and eluting the AAV adsorbed to the adsorbent using an eluent.
[0183] Hereinafter, the present invention will be described in detail. However, the present invention is not limited to the following embodiments, and can be implemented in any form within the scope of the present invention.
[0184] It should be noted that the patent publications, patent application publications, non-patent literature, etc. cited in this specification may be cited in their entirety and may be incorporated into the present invention for any purpose.
[0185] The AAV binding protein described in the present specification refers to the following protein: at least it contains the amino acid residues from serine (Ser) at position 312 to aspartic acid (Asp) at position 500 in the extracellular region domain 1 (PKD1) and domain 2 (PKD2) in the amino acid sequence corresponding to KIAA0319L recorded in sequence number 1 (official database: UniProt, accession number: Q8IZA0), and amino acid substitutions at specific positions occur in the amino acid residues from positions 312 to 500. Therefore, the AAV binding protein of the present invention may include all or part of other extracellular region domains (domain 3 (PKD3), domain 4 (PKD4) and domain 5 (PKD5)) located on the C-terminal side of the protein, and may also include all or part of the signal sequence such as the MANSC (Motif At N terminus with Seven Cysteines) domain located on the N-terminal side of PKD1, and the cysteine-rich region, and may also include the transmembrane region located on the N-terminal side and / or C-terminal side of the extracellular region and all or part of the intracellular region.
[0186] Specifically, the amino acid substitution at the specific position refers to the generation of Ile319Phe (this mark indicates that the isoleucine at position 319 of sequence number 1 is substituted with phenylalanine, and the same applies hereinafter), Leu321Pro, Pro322Leu, Asn324Asp, Asn324Ser, Gln327Arg, Asn329Asp, Asn329Tyr, Ala330Gly, Tyr331Cys, Val332Gln, Leu333Val, Leu333Pro, Gln334Arg, Pro337Leu, Lys338Arg, L ys338Glu, Glu340Gly, Thr341Ala, Tyr342Cys, Tyr342His, Tyr342Asn, Thr343Met, Tyr344His, Asp345Asn, Trp346Leu, Trp346Arg, Gln347Le u, Gln347Pro, Leu348Pro, Ile349Thr, Thr350Met, His351Leu, Pro352Leu, Arg353Cys, Asp354Gly, Tyr355His, Tyr355Asn, Tyr355Cys, Ser35 6Cys, Gly357Cys, His363Arg, His363Leu, Ser364Pro, Gln365Arg, Ile366Thr, Leu367Pro, Lys368Arg, Leu369Gln, Leu369Pro, Ser370Ala, Ly s371Glu, Thr373Ala, Leu376Pro, Tyr377Cys, Phe379Ser, Val381Ala, Glu384Gly, Asn387Ser, His389Gln, His389Leu, His389Arg, Gly390Ser , Glu391Lys, Tyr393Cys, Val396Ala, Lys399Glu, Lys399Arg, Arg406Ser, Val412Ala, Gln415Leu, Phe416Ser, Gln441Leu, Tyr442Phe, Lys448Arg, Glu453Gly, Lys455Arg, Glu458Gly, Ala461Ser, Ser476Arg, Leu477Pro, Asn487Asp and Asn492Asp are preferably used because the stability to heat and / or acid is improved.
[0187] Among them, Gly390Ser is an amino acid substitution that particularly improves the stability against heat and acid. Therefore, an AAV-binding protein having at least the amino acid substitution of Gly390Ser is a preferred embodiment of the AAV-binding protein of the present invention.
[0188] In addition, in the amino acid sequence recorded in SEQ ID NO: 1, when at least one of Ile319Asn, Ile319Ser, Thr320Ile, Lys323Glu, Leu328Gln, Leu328Pro, Tyr331His, Val332Ala, Val332Glu, Pro336Gln, Pro337Gln, Lys338Asn, Tyr342Arg, Thr350Ser, Ile366Phe, Val383Ala, Gln386Arg, His389Asp, Gly392Cys, Val394Ala, Ile409Val, Ser476Gly and Thr490Ser is substituted, the stability to heat and / or acid is improved, which is preferred.
[0189] In addition, in the amino acid sequence recorded in SEQ ID NO: 1, when at least one of Val317Asp, Gln318Pro, Thr320Ala, Val326Ala, Val326Glu, Leu328Pro, Asn329His, Val332Ala, Lys362Glu, Lys362Asn, Lys371Asn, Leu376Pro, Glu378Gly, Glu378Val, Phe379Tyr, Phe379Ser, Val381Asp, Thr397Ser, Glu401Val, Arg406His and Val499Glu is substituted, the stability to heat and / or acid is improved, which is preferred.
[0190] Furthermore, in the amino acid sequence described in SEQ ID NO: 1, Ser312Pro, Ala313Ser, Lys323Arg, Asn324Ser, Gln327His, Gln327Leu, Asn329Ile, Glu335Gly, Glu335Val, Glu340Val, Thr341Pro, Thr343Ser, Tyr344Phe, Trp346Cys, Ar g353Cys, Tyr355Cys, Ser356Cys, Gly357Cys, Met359Leu, Glu360Lys, Glu360Val, Gly361Cys, Lys3 62Gly, Ser364Leu, Ile366Thr, Leu369Gln, Lys371Asp, Leu372Pro, Leu372Gln, Thr373Ala, Pro374 Leu, Leu376Pro, Glu378Gly, Glu378Val, Phe379Cys, Phe379Ser, Lys380Glu, Val381Ala, Ile382V al, Val383Ala, Glu384Val, Gln386Arg, His389Arg, Tyr393Cys, Val394Asp, Val394Ile, Asn395Ser , Val396Ala, Arg403His, Gln415Arg, Thr426Ala, Gln432Leu, Gln432Arg, Gln441Arg, His443Leu, Lys448Glu, Ile456Val, Asp483Asn, Ser488Leu, and Val499Ile are preferably substituted because the stability to heat and / or alkali is improved.
[0191] In the AAV binding protein of the present invention, there is no particular limitation on the number of substituted amino acids. As an example, the AAV binding proteins shown in (A) to (K) below can be cited. These AAV binding proteins are more preferred from the viewpoint of improving the stability to heat and acid.
[0192] (A) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser and Tyr342Cys occur in the amino acid residues at positions 312 to 500.
[0193] (B) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Tyr342Cys and Ser476Arg have occurred among the amino acid residues at positions 312 to 500.
[0194] (C) An AAV binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Ile319Phe, Tyr342Cys and Ser476Arg have occurred among the amino acid residues at positions 312 to 500.
[0195] (D) An AAV binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Tyr342Cys, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0196] (E) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Ile319Phe, Lys323Glu, Tyr342Cys and Ser476Arg are produced among the amino acid residues at positions 312 to 500.
[0197] (F) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Tyr342Cys, Lys399Glu, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0198] (G) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Asn324Asp, Tyr342Cys, Lys362Glu, Lys399Glu, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0199] (H) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Val317Asp, Tyr342Cys, Lys371Asn, Lys399Glu, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0200] (I) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Val317Asp, Asn324Asp, Tyr342Cys, Lys362Glu, Lys399Glu, Ser476Arg and Asn487Asp have occurred in the amino acid residues from position 312 to position 500.
[0201] (J) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Val317Asp, Tyr342Cys, Lys362Glu, Lys371Asn, Lys399Glu, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0202] (K) An AAV-binding protein comprising the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence recorded in SEQ ID NO: 1, and at least amino acid substitutions of Gly390Ser, Val317Asp, Tyr(Cys)342Ser, Lys362Glu, Lys371Asn, Val381Ala, Ile382Val, Lys399Glu, Ser476Arg and Asn487Asp occur among the amino acid residues at positions 312 to 500.
[0203] More specifically, the AAV-binding proteins of the present invention include the following AAV-binding proteins. These AAV-binding proteins are preferred because they have improved stability to heat and acid.
[0204] As one embodiment of the AAV-binding protein shown in (A), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 18.
[0205] As one embodiment of the AAV-binding protein shown in (B), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 32.
[0206] As one embodiment of the AAV-binding protein shown in (C), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 34.
[0207] As one embodiment of the AAV-binding protein shown in (D), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 38.
[0208] As one embodiment of the AAV-binding protein shown in (E), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 42.
[0209] As one embodiment of the AAV-binding protein shown in (F), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 46.
[0210] As one embodiment of the AAV-binding protein represented by (G), an AAV-binding protein comprises at least the amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 53.
[0211] As one embodiment of the AAV-binding protein shown in (H), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 55.
[0212] As one embodiment of the AAV-binding protein shown in (I) above, an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 59.
[0213] As one embodiment of the AAV-binding protein shown in (J), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 63.
[0214] As one embodiment of the AAV-binding protein represented by (K), an AAV-binding protein comprises at least an amino acid sequence from serine at position 25 to aspartic acid at position 231 in the amino acid sequence described in SEQ ID NO: 69.
[0215] In addition, more specifically, the AAV-binding protein of the present invention includes the following AAV-binding proteins: The AAV-binding protein is preferred from the viewpoint of improving thermal stability.
[0216] As one embodiment of the AAV-binding protein shown in (F), an AAV-binding protein comprises at least the amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO: 76.
[0217] In (ii), (v) and (viii), "one or more" varies depending on the position of the amino acid substitution in the three-dimensional structure of the AAV binding protein and the type of amino acid residue, but as an example, it refers to any of 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, and 1. As an example of the amino acid substitution, conservative substitutions in which substitutions are made between amino acids with similar physical and / or chemical properties can be listed. It is known to those skilled in the art that in the case of conservative substitutions, the function of the protein is usually maintained between the substitution and the non-substitution. As an example of conservative substitutions, substitutions between glycine and alanine, between serine and proline, or between glutamic acid and alanine can be listed (Structure and Function of Proteins, MEDICALSCIENCES INTERNATIONAL, LTD., 9, 2005). In addition, as other examples of the amino acid substitution, substitution for monomerizing the AAV-binding protein of the present invention can be cited. Specifically, amino acid substitutions that replace cysteine residues that easily form a high-dimensional structure with serine residues or methionine residues can be cited.
[0218] In the present specification, any one or more of substitution, deletion, insertion and addition also include naturally occurring mutations (mutants or variants) derived from differences in AAV binding proteins and species differences.
[0219] The homology of the amino acid sequences in (iii), (vi) and (ix) may be 70% or more, or may have a higher homology (for example, 80% or more, 85% or more, 90% or more, 95% or more, or 98% or more). It should be noted that the "homology" in this specification refers to similarity or identity, and particularly refers to identity. "Amino acid sequence homology" refers to the homology relative to the entire amino acid sequence. "Identity" between amino acid sequences refers to the ratio of amino acid residues of the same type in these amino acid sequences (Experimental Medicine, February 2013, Vol. 31 No. 3, Yang Tushe). "Similarity" between amino acid sequences refers to the sum of the ratio of amino acid residues of the same type in these amino acid sequences and the ratio of amino acid residues with similar properties of the side chains (Experimental Medicine, February 2013, Vol. 31 No. 3, Yang Tushe). The homology of amino acid sequences can be determined using alignment programs such as BLAST (Basic Local Alignment Search Tool) and FASTA.
[0220] The AAV binding protein of the present invention may further have an oligopeptide added to its N-terminal side or C-terminal side that facilitates separation from a solution in the presence of inclusions. Examples of the aforementioned oligopeptide include polyhistidine, polylysine, polyarginine, polyglutamic acid, polyaspartic acid, and the like. In addition, an oligopeptide containing cysteine (e.g., an oligopeptide composed of amino acid residues ranging from cysteine at position 220 to glycine at position 226 in the amino acid sequence recorded in SEQ ID NO: 50) useful for fixing the AAV binding protein of the present invention to a solid phase such as a chromatographic support may also be further added to the N-terminal side or C-terminal side of the AAV binding protein of the present invention.
[0221] The length of the oligopeptide added to the N-terminal side or C-terminal side of the AAV binding protein is not particularly limited as long as it does not impair the AAV binding and stability of the AAV binding protein of the present invention. When the oligopeptide is added to the AAV binding protein of the present invention, it can be added to the N-terminal side or C-terminal side of the AAV binding protein by genetic engineering means using methods well known to those skilled in the art after preparing a polynucleotide encoding the oligopeptide, or it can be added by chemically binding the chemically synthesized oligopeptide to the N-terminal side or C-terminal side of the AAV binding protein of the present invention.
[0222] Furthermore, a signal peptide for promoting efficient expression in a host can also be added to the N-terminal side of the AAV binding protein of the present invention. When the host is Escherichia coli, examples of the signal peptide include signal peptides such as PeIB, OmpA, DsbA, DsbC, MalE, TorT, etc., which secrete proteins into the periplasm (Japanese Patent Application Laid-Open No. 2011-097898).
[0223] In the present specification, "improved stability to heat, acid or alkali" may refer to improved stability to heat, acid or alkali compared to the wild-type AAV binding protein (a protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence recorded in sequence number 7), preferably, it may refer to improved stability to heat and acid or alkali, and more preferably, it may refer to improved stability to heat, acid and alkali.
[0224] An example of a method for producing a polynucleotide encoding the AAV-binding protein of the present invention (hereinafter also referred to as the polynucleotide of the present invention) can be exemplified as follows:
[0225] (I) a method for converting the amino acid sequence of the AAV binding protein of the present invention into a nucleotide sequence and artificially synthesizing a polynucleotide comprising the nucleotide sequence;
[0226] (II) A method of directly synthesizing a polynucleotide containing the entire or partial sequence of an AAV binding protein, or preparing the polynucleotide from the cDNA of an AAV binding protein using a DNA amplification method such as PCR, and then ligating the prepared polynucleotide using an appropriate method.
[0227] In the method of aforementioned (I), when amino acid sequence is converted into nucleotide sequence, it is preferred to consider the usage frequency of the codon in the transformed host and convert. As an example, when the host is Escherichia coli, the usage frequency of AGA / AGG / CGG / CGA in the case of arginine (Arg) is less, the usage frequency of ATA in the case of isoleucine (Ile) is less, the usage frequency of CTA in the case of leucine (Leu) is less, the usage frequency of GGA in the case of glycine (Gly) is less, and the usage frequency of CCC in the case of proline (Pro) is less (because it is a so-called rare codon), so these codons can be avoided and converted. The analysis of the usage frequency of codons can be carried out using a known database (for example, Codon Usage Database in the website of Kazusa DNA Research Institute., etc.).
[0228] When introducing mutations into the polynucleotide of the present invention, the error-prone PCR method can be used. The reaction conditions in the error-prone PCR method are not particularly limited as long as they are conditions that can introduce the desired mutations into the polynucleotide encoding the AAV binding protein. For example, the concentrations of the four deoxynucleotides (dATP / dTTP / dCTP / dGTP) as substrates are made uneven, and MnCl2 is added to the PCR reaction solution at a concentration of 0.01 to 10 mM (preferably 0.1 to 1 mM) to perform PCR, thereby enabling the introduction of mutations into the polynucleotide. In addition, as a mutation introduction method other than the error-prone PCR method, the following methods can be cited: a polynucleotide containing the entire or partial sequence of the AAV binding protein is contacted / acted with a reagent as a mutagen, irradiated with ultraviolet light, or a mutation is introduced into the polynucleotide to make it. In this method, as a reagent used as a mutagen, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine, nitrous acid, sulfurous acid, hydrazine, etc., mutagens commonly used by those skilled in the art can be used.
[0229] When the polynucleotide of the present invention is used to transform a host, the polynucleotide of the present invention itself can be used, and more preferably, a substance formed by inserting the polynucleotide of the present invention at an appropriate site of an expression vector (e.g., a phage, cosmid, plasmid, etc. commonly used in the transformation of prokaryotic cells and eukaryotic cells). It should be noted that the expression vector is not particularly limited as long as it is an expression vector that can stably exist and replicate in the transformed host. When Escherichia coli is used as a host, pET plasmid vectors, pUC plasmid vectors, pTrc plasmid vectors, and pCDF plasmid vectors can be exemplified.
[0230] In addition, the appropriate site refers to a site that does not destroy the replication function of the expression vector, the desired antibiotic marker, and the region related to conductivity. When inserting the polynucleotide of the present invention into the expression vector, it is preferably inserted in a state of being linked to a functional polynucleotide such as a promoter required for expression. Examples of such promoters include trp promoter, tac promoter, trc promoter, lac promoter, T7 promoter, recA promoter, and lpp promoter when the host is Escherichia coli.
[0231] The host can be transformed using the expression vector prepared by the aforementioned method and into which the polynucleotide of the present invention is inserted (hereinafter referred to as the expression vector of the present invention) by the method commonly used by those skilled in the art. For example, when a microorganism belonging to the genus Escherichia (Escherichia coli JM109 strain, Escherichia coli BL21 (DE3) strain, Escherichia coli W3110 strain, etc.) is selected as the host, the transformation can be carried out by the method described in the known literature (for example, Molecular Cloning, Cold Spring Harbor Laboratory, 256, 1992). The transformant obtained by the aforementioned method can be screened by an appropriate method to obtain a transformant that can express the AAV binding protein of the present invention (hereinafter referred to as the transformant of the present invention).
[0232] When the expression vector of the present invention is prepared from the transformant of the present invention, it can be prepared from the culture obtained by culturing the transformant of the present invention using an alkali extraction method or a commercially available extraction kit such as QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0233] The AAV binding protein of the present invention can be produced by culturing the transformant of the present invention and recovering the AAV binding protein of the present invention from the obtained culture. It should be noted that in this specification, the culture includes not only the cells of the cultured transformant of the present invention but also the medium used in the culture.
[0234] The transformant used in the protein production method of the present invention can be cultured in a medium suitable for the target host culture. When the host is Escherichia coli, an example of a preferred culture medium is LB (Luria-Bertani) medium supplemented with necessary nutrient sources. It should be noted that in order to selectively proliferate the transformant of the present invention by the presence or absence of the introduction of the vector of the present invention, it is preferred to add a drug corresponding to the agent resistance gene contained in the vector to the culture medium for culture. For example, when the vector contains a kanamycin resistance gene, kanamycin can be added to the culture medium.
[0235] In addition, in addition to carbon, nitrogen and inorganic salt sources, appropriate nutrient sources may be added to the culture medium, and one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolic acid and dithiothreitol may be included as desired. When the host is Escherichia coli, the culture temperature is usually 10°C to 40°C, preferably 20°C to 37°C, and more preferably about 25°C, which can be selected according to the characteristics of the expressed protein. When the host is Escherichia coli, the pH of the culture medium is pH 6.8 to pH 7.4, preferably about pH 7.0. In addition, when the vector of the present invention contains an inducible promoter, it is preferred to apply induction under conditions where the AAV binding protein of the present invention can be well expressed.
[0236] As an inducer, IPTG (Isopropyl-β-D-thiogalactopyranoside) can be exemplified. When the host is Escherichia coli, the turbidity of the culture solution (absorbance at 600nm) is measured. When it reaches about 0.5 to 1.0, an appropriate amount of IPTG is added, and the culture is continued, thereby inducing the expression of AAV binding protein. The concentration of IPTG added can be appropriately selected from the range of 0.005 to 1.0 mM, but is preferably in the range of 0.01 to 0.5 mM. The various conditions involved in IPTG induction can be carried out according to the conditions known in the technical field.
[0237] In order to recover the AAV binding protein of the present invention from the culture obtained by culturing the transformant of the present invention, the AAV binding protein of the present invention can be recovered by separation / purification from the culture using a method suitable for the expression form of the AAV binding protein of the present invention in the transformant of the present invention. For example, when expressing in the culture supernatant, the bacterial cells can be separated by centrifugation, and the AAV binding protein of the present invention can be purified from the obtained culture supernatant. In addition, when expressing in cells (including periplasm), the bacterial cells can be collected by centrifugation, and then an enzyme treatment agent, a surfactant, etc. can be added to break the bacterial cells, and the AAV binding protein of the present invention can be extracted and purified.
[0238] In order to purify the AAV-binding protein of the present invention, a method known in the art can be used, and separation / purification using liquid chromatography can be cited as an example. Liquid chromatography includes ion exchange chromatography, hydrophobic interaction chromatography, gel filtration chromatography, affinity chromatography, etc., and by combining these chromatography to perform purification operations, the AAV-binding protein of the present invention can be prepared with high purity.
[0239] As a method for measuring the binding activity of the AAV binding protein of the present invention to AAV, for example, an enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance can be used to measure the binding activity to AAV. The AAV used in the determination of the binding activity may be an AAV vector or a VLP (virus-like particle). In addition, as long as the binding activity to the AAV binding protein of the present invention is shown, AAV vectors and VLPs of any serum type (serotype) can be used.
[0240] The AAV binding protein of the present invention can be used, for example, for the purification or analysis of AAV. The AAV binding protein of the present invention can be used, for example, by being fixed to an insoluble carrier. That is, the purification or analysis of AAV can be specifically implemented, for example, using an AAV adsorbent, which contains an insoluble carrier and the AAV binding protein of the present invention fixed to the insoluble carrier. In this specification, an AAV adsorbent comprising an insoluble carrier and the AAV binding protein of the present invention fixed to the insoluble carrier is also referred to as the AAV adsorbent of the present invention. It should be noted that the purification of AAV is not limited to purifying AAV from a solution where impurities coexist, but also includes purification of AAV based on structure, properties or activity. There is no particular limitation on the insoluble carrier. As insoluble carriers, examples include: carriers with polysaccharides such as agarose, alginate (Arginate), carrageenan, chitin, cellulose, dextrin, dextran, starch as raw materials; carriers with synthetic polymers such as polyvinyl alcohol, polymethacrylate, poly (2-hydroxyethyl methacrylate), polyurethane as raw materials; carriers with ceramics such as silica as raw materials. Among them, as insoluble carriers, carriers with polysaccharides as raw materials and carriers with synthetic polymers as raw materials are preferred. As an example of the preferred carrier, polymethacrylate gels such as TOYOPEARL (TOSOHCORPORATION.), agarose gels such as Sepharose (Cytiva), and cellulose gels such as Cellufine (JNC) can be listed. There is no particular limitation on the shape of the insoluble carrier. The insoluble carrier can be, for example, a shape that can be filled in a column. The insoluble carrier can be, for example, a granular object, a monolithic object, a film-like object, a fibrous object, etc. Additionally, the insoluble carrier may be, for example, porous or non-porous.
[0241] The AAV binding protein of the present invention can be fixed to an insoluble carrier, for example, by a covalent bond. Specifically, the AAV binding protein of the present invention can be fixed to an insoluble carrier by covalently bonding the AAV binding protein of the present invention to an insoluble carrier, for example, through an active group possessed by the insoluble carrier. That is, the insoluble carrier can have an active group. The insoluble carrier can, for example, have an active group on its surface. As active groups, N-hydroxysuccinimide (NHS) activated ester group, epoxy group, carboxyl group, maleimide group, haloacetyl group, trifluoroethanesulfonyl group (Tresyl), formyl group, and haloacetamide group can be listed. As an insoluble carrier having an active group, for example, a commercially available insoluble carrier having an active group can be used directly; it can also be used by introducing an active group into an insoluble carrier. Examples of commercially available carriers having active groups include TOYOPEARL AF-Epoxy-650M, TOYOPEARL AF-Tresyl-650M (all manufactured by TOSOH CORPORATION), HiTrap NHS-activated HP Columns, NHS-activated Sepharose 4FastFlow, Epoxy-activated Sepharose 6B (all manufactured by Cytiva), and SulfoLink Coupling Resin (manufactured by Thermo Fisher Scientific Inc.).
[0242] Examples of methods for introducing active groups into the support surface include a method of reacting one of a compound having two or more active sites with a hydroxyl group, epoxy group, carboxyl group, amino group, etc. present on the support surface.
[0243] Examples of the compound that introduces an epoxy group into a hydroxyl group or an amino group present on the surface of the carrier include epichlorohydrin, ethylene glycol diglycidyl ether, butanediol diglycidyl ether, and hexanediol diglycidyl ether.
[0244] Examples of the compound for introducing a carboxyl group into an epoxy group present on the surface of the carrier include 2-mercaptoacetic acid, 3-mercaptopropionic acid, 4-mercaptobutyric acid, 6-mercaptobutyric acid, glycine, 3-aminopropionic acid, 4-aminobutyric acid, and 6-aminocaproic acid.
[0245] Examples of compounds for introducing maleimide groups into hydroxyl groups, epoxy groups, carboxyl groups, and amino groups present on the surface of the carrier include N-(ε-maleimidocaproic acid)hydrazide, N-(ε-maleimidocaproic acid)hydrazide, 4-(4-N-maleimidophenyl)acetohydrazide, 2-aminomaleimide, 3-aminomaleimide, 4-aminomaleimide, 6-aminomaleimide, 1-(4-aminophenyl)maleimide, 1-(3-aminophenyl)maleimide, 4-(maleimide)phenylisocyanate, 2-maleimide Aminoacetic acid, 3-maleimidopropionic acid, 4-maleimidobutyric acid, 6-maleimidocaproic acid, N-(α-maleimidoacetoxy)succinimide ester, (maleimido-m-benzoyl) N-hydroxysuccinimide ester, succinimidyl-4-(maleimidomethyl)cyclohexane-1-carbonyl-6-aminohexanoic acid, succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylic acid, (maleimido-p-benzoyl) N-hydroxysuccinimide ester, (maleimido-m-benzoyl) N-hydroxysuccinimide ester.
[0246] In addition, examples of compounds for introducing haloacetyl groups into hydroxyl groups and amino groups present on the surface of the carrier include: chloroacetic acid, bromoacetic acid, iodoacetic acid, chloroacetyl chloride, bromoacetyl chloride, bromoacetyl bromide, chloroacetic anhydride, bromoacetic anhydride, iodoacetic anhydride, 2-(iodoacetamide)acetic acid-N-hydroxysuccinimide ester, 3-(bromoacetamide)propionic acid-N-hydroxysuccinimide ester, and 4-(iodoacetyl)aminobenzoic acid-N-hydroxysuccinimide ester.
[0247] In addition, as a method for introducing active groups to the surface of the carrier, a method of activating the ω-alkenyl site by halogenating with a halogenating agent after reacting the hydroxyl group or amino group present on the surface of the carrier with an ω-alkenyl alkyl glycidyl ether can also be exemplified. As ω-alkenyl alkyl glycidyl ether, allyl glycidyl ether, 3-butenyl glycidyl ether, and 4-pentenyl glycidyl ether can be exemplified. As a halogenating agent, N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide can be exemplified.
[0248] In addition, as a method for introducing active groups to the carrier surface, a method for introducing active groups using a condensing agent and an additive to the carboxyl groups present on the carrier surface can also be exemplified. As condensing agents, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), dicyclohexylcarbodiimide, and carbonyldiimidazole can be exemplified. In addition, as additives, N-hydroxysuccinimide (NHS), 4-nitrophenol, and 1-hydroxybenzotriazole can be exemplified.
[0249] The fixation of the AAV binding protein of the present invention to an insoluble carrier can be implemented, for example, in a buffer. Examples of the buffer include: acetate buffer, phosphate buffer, MES (2-morpholineethanesulfonic acid) buffer, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, Tris buffer (tris(hydroxymethyl)aminomethane), and boric acid buffer. The reaction temperature when fixing it can be appropriately set, for example, based on the reactivity of the active group, the stability of the AAV binding protein, and other conditions. The reaction temperature when fixing it can be, for example, 5°C to 50°C, preferably 10°C to 35°C.
[0250] The AAV adsorbent of the present invention can be filled in a column and used for the purification of AAV, for example. Specifically, for example, a solution containing AAV is added to a column filled with the AAV adsorbent of the present invention, so that the adsorbent adsorbs the AAV, and the AAV adsorbed to the adsorbent is eluted, thereby purifying AAV. That is, the present invention provides, for example, a method for purifying AAV, which includes: adding a solution containing AAV to a column filled with the AAV adsorbent of the present invention, so that the adsorbent adsorbs the AAV; and, a process of eluting the AAV adsorbed to the adsorbent. The solution containing AAV can be added to the column using a liquid supply unit such as a pump. It should be noted that in this specification, adding liquid to the column is also referred to as "sending liquid to the column". It should be noted that the solution containing AAV can be pre-solvent-substituted using a suitable buffer before being added to the column. In addition, the column can also be equilibrated using a suitable buffer before adding the solution containing AAV to the column. Through the equilibration, it can be expected that, for example, AAV can be purified with a higher purity. As the buffer used in solvent replacement and equilibration, phosphate buffer, acetate buffer, and MES buffer can be exemplified. Inorganic salts such as 10mM to 100mM sodium chloride can be further added to such a buffer. The buffer used in solvent replacement and the buffer used in equilibration can be optionally the same or different. In addition, after the solution containing AAV is passed through the column, if there are components other than AAV such as inclusions in the column, such components can be removed from the column before eluting the AAV adsorbed on the AAV adsorbent. Components other than AAV can be removed from the column using a suitable buffer, for example. For the buffer used in the removal of components other than AAV, for example, the description of the buffer used in solvent replacement and equilibration can be used. AAV adsorbed on the AAV adsorbent can be eluted, for example, by weakening the interaction between AAV and the ligand (AAV binding protein of the present invention). As a means of weakening the interaction between AAV and the ligand (AAV binding protein of the present invention), examples include: changing the pH using a buffer, adding a counter peptide, increasing the temperature, and changing the salt concentration. Specifically, the AAV adsorbed on the AAV adsorbent can be eluted using a suitable eluent, for example. As the eluent, a buffer closer to the acidic side than the buffer used in solvent replacement and equilibration can be cited. As such a buffer, citric acid buffer, glycine hydrochloride buffer, and acetate buffer can be exemplified. The pH of the eluent can be set within a range that does not, for example, impair the function of AAV (binding property to antigens, etc.).
[0251] By implementing the purification of AAV in this way, for example, purified AAV can be obtained. That is, the purification method of AAV can be a method for manufacturing AAV in one mode, specifically, it can be a method for manufacturing purified AAV. AAV can be obtained, for example, in the form of an eluted fraction containing AAV. That is, the fraction containing the eluted AAV can be fractionated. The fractionation of AAV fractions can be carried out, for example, according to conventional methods. As methods for fractionating AAV fractions, there can be listed: a method of replacing the recovery container at regular intervals and at regular volumes; a method of replacing the recovery container in combination with the chromatogram shape of the eluate; a method of fractionating fractions using an automatic fraction collector such as an automatic sampler. Furthermore, AAV can also be recovered from the fraction containing AAV. The recovery of AAV from the fraction containing AAV can be carried out, for example, by a known method used in the purification of proteins.
[0252] Effects of the Invention
[0253] The adeno-associated virus (AAV) binding protein of the present invention is a protein obtained by replacing the amino acid residues at specific sites in the extracellular region of the AAV receptor with other amino acid residues. The AAV binding protein of the present invention has improved stability to heat, acid and alkali compared to the wild type (AAV binding protein in which the amino acid residues are not replaced). Therefore, the AAV binding protein of the present invention is useful as a ligand for an adsorbent for purifying AAV vectors. In addition, an AAV adsorbent comprising an insoluble carrier and the AAV binding protein of the present invention fixed to the carrier can purify the AAV vector contained in the solution with high purity compared to an AAV adsorbent comprising an insoluble carrier and a wild-type AAV binding protein fixed to the carrier. Sequence Listing <110> TOSOH Corporation <120> Improved adeno-associated virus binding protein, method for producing the protein, and adeno-associated virus adsorbent using the protein <130> P200633WO <150> JP2019-212020 <151> 2019-11-25 <150> JP2020-165229 <151> 2020-09-30 <160> 77 <170> PatentIn version 3.5 <210> 1 <211> 1049 <212> PRT <213> Homo sapiens <300> <308> UniProt Q8IZA0 <313> (1)..(1048) <400> 1 Met Glu Lys Arg Leu Gly Val Lys Pro Asn Pro Ala Ser Trp Ile Leu 1 5 10 15 Ser Gly Tyr Tyr Trp Gln Thr Ser Ala Lys Trp Leu Arg Ser Leu Tyr 20 25 30 Leu Phe Tyr Thr Cys Phe Cys Phe Ser Val Leu Trp Leu Ser Thr Asp 35 40 45 Ala Ser Glu Ser Arg Cys Gln Gln Gly Lys Thr Gln Phe Gly Val Gly 50 55 60 Leu Arg Ser Gly Gly Glu Asn His Leu Trp Leu Leu Glu Gly Thr Pro 65 70 75 80 Ser Leu Gln Ser Cys Trp Ala Ala Cys Cys Gln Asp Ser Ala Cys His 85 90 95 Val Phe Trp Trp Leu Glu Gly Met Cys Ile Gln Ala Asp Cys Ser Arg 100 105 110 Pro Gln Ser Cys Arg Ala Phe Arg Thr His Ser Ser Asn Ser Met Leu 115 120 125 Val Phe Leu Lys Lys Phe Gln Thr Ala Asp Asp Leu Gly Phe Leu Pro 130 135 140 Glu Asp Asp Val Pro His Leu Leu Gly Leu Gly Trp Asn Trp Ala Ser 145 150 155 160 Trp Arg Gln Ser Pro Pro Arg Ala Ala Leu Arg Pro Ala Val Ser Ser 165 170 175 Ser Asp Gln Gln Ser Leu Ile Arg Lys Leu Gln Lys Arg Gly Ser Pro 180 185 190 Ser Asp Val Val Thr Pro Ile Val Thr Gln His Ser Lys Val Asn Asp 195 200 205 Ser Asn Glu Leu Gly Gly Leu Thr Thr Ser Gly Ser Ala Glu Val His 210 215 220 Lys Ala Ile Thr Ile Ser Ser Pro Leu Thr Thr Asp Leu Thr Ala Glu 225 230 235 240 Leu Ser Gly Gly Pro Lys Asn Val Ser Val Gln Pro Glu Ile Ser Glu 245 250 255 Gly Leu Ala Thr Thr Pro Ser Thr Gln Gln Val Lys Ser Ser Glu Lys 260 265 270 Thr Gln Ile Ala Val Pro Gln Pro Val Ala Pro Ser Tyr Ser Tyr Ala 275 280 285 Thr Pro Thr Pro Gln Ala Ser Phe Gln Ser Thr Ser Ala Pro Tyr Pro 290 295 300 Val Ile Lys Glu Leu Val Val Ser Ala Gly Glu Ser Val Gln Ile Thr 305 310 315 320 Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu Pro 325 330 335 Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His Pro 340 345 350 Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu Lys 355 360 365 Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val Glu 370 375 380 Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys Pro 385 390 395 400 Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln Phe 405 410 415 Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser Gln 420 425 430 Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu Lys 435 440 445 Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu Lys 450 455 460 Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val Val 465 470 475 480 Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val Asn 485 490 495 Lys Ala Val Asp Tyr Pro Pro Val Ala Asn Ala Gly Pro Asn Gln Val 500 505 510 Ile Thr Leu Pro Gln Asn Ser Ile Thr Leu Phe Gly Asn Gln Ser Thr 515 520 525 Asp Asp His Gly Ile Thr Ser Tyr Glu Trp Ser Leu Ser Pro Ser Ser 530 535 540 Lys Gly Lys Val Val Glu Met Gln Gly Val Arg Thr Pro Thr Leu Gln 545 550 555 560 Leu Ser Ala Met Gln Glu Gly Asp Tyr Thr Tyr Gln Leu Thr Val Thr 565 570 575 Asp Thr Ile Gly Gln Gln Ala Thr Ala Gln Val Thr Val Ile Val Gln 580 585 590 Pro Glu Asn Asn Lys Pro Pro Gln Ala Asp Ala Gly Pro Asp Lys Glu 595 600 605 Leu Thr Leu Pro Val Asp Ser Thr Thr Leu Asp Gly Ser Lys Ser Ser 610 615 620 Asp Asp Gln Lys Ile Ile Ser Tyr Leu Trp Glu Lys Thr Gln Gly Pro 625 630 635 640 Asp Gly Val Gln Leu Glu Asn Ala Asn Ser Ser Val Ala Thr Val Thr 645 650 655 Gly Leu Gln Val Gly Thr Tyr Val Phe Thr Leu Thr Val Lys Asp Glu 660 665 670 Arg Asn Leu Gln Ser Gln Ser Ser Val Asn Val Ile Val Lys Glu Glu 675 680 685 Ile Asn Lys Pro Pro Ile Ala Lys Ile Thr Gly Asn Val Val Ile Thr 690 695 700 Leu Pro Thr Ser Thr Ala Glu Leu Asp Gly Ser Lys Ser Ser Asp Asp 705 710 715 720 Lys Gly Ile Val Ser Tyr Leu Trp Thr Arg Asp Glu Gly Ser Pro Ala 725 730 735 Ala Gly Glu Val Leu Asn His Ser Asp His His Pro Ile Leu Phe Leu 740 745 750 Ser Asn Leu Val Glu Gly Thr Tyr Thr Phe His Leu Lys Val Thr Asp 755 760 765 Ala Lys Gly Glu Ser Asp Thr Asp Arg Thr Thr Val Glu Val Lys Pro 770 775 780 Asp Pro Arg Lys Asn Asn Leu Val Glu Ile Ile Leu Asp Ile Asn Val 785 790 795 800 Ser Gln Leu Thr Glu Arg Leu Lys Gly Met Phe Ile Arg Gln Ile Gly 805 810 815 Val Leu Leu Gly Val Leu Asp Ser Asp Ile Ile Val Gln Lys Ile Gln 820 825 830 Pro Tyr Thr Glu Gln Ser Thr Lys Met Val Phe Phe Val Gln Asn Glu 835 840 845 Pro Pro His Gln Ile Phe Lys Gly His Glu Val Ala Ala Met Leu Lys 850 855 860 Ser Glu Leu Arg Lys Gln Lys Ala Asp Phe Leu Ile Phe Arg Ala Leu 865 870 875 880 Glu Val Asn Thr Val Thr Cys Gln Leu Asn Cys Ser Asp His Gly His 885 890 895 Cys Asp Ser Phe Thr Lys Arg Cys Ile Cys Asp Pro Phe Trp Met Glu 900 905 910 Asn Phe Ile Lys Val Gln Leu Arg Asp Gly Asp Ser Asn Cys Glu Trp 915 920 925 Ser Val Leu Tyr Val Ile Ile Ala Thr Phe Val Ile Val Val Ala Leu 930 935 940 Gly Ile Leu Ser Trp Thr Val Ile Cys Cys Cys Lys Arg Gln Lys Gly 945 950 955 960 Lys Pro Lys Arg Lys Ser Lys Tyr Lys Ile Leu Asp Ala Thr Asp Gln 965 970 975 Glu Ser Leu Glu Leu Lys Pro Thr Ser Arg Ala Gly Ile Lys Gln Lys 980 985 990 Gly Leu Leu Leu Ser Ser Ser Leu Met His Ser Glu Ser Glu Leu Asp 995 1000 1005 Ser Asp Asp Ala Ile Phe Thr Trp Pro Asp Arg Glu Lys Gly Lys 1010 1015 1020 Leu Leu His Gly Gln Asn Gly Ser Val Pro Asn Gly Gln Thr Pro 1025 1030 1035 Leu Lys Ala Arg Ser Pro Arg Glu Glu Ile Leu 1040 1045 <210> 2 <211> 567 <212> DNA <213> Artificial Sequence <220> <223> AAVR PKD1 and PKD2 DNA <400> 2 tctgcaggcg agtcggttca gattaccctg ccgaagaacg aagtacaact gaatgcgtat 60 gtgctgcagg aaccaccgaa aggggaaacc tatacgtatg actggcagct tattacgcat 120 cctcgcgact acagcggcga gatggaagga aaacattcgc agattctgaa actgtccaaa 180 ctgacgccgg gtctgtatga attcaaggtt atcgttgaag gtcagaatgc acatggcgaa 240 ggctatgtta acgttaccgt gaaaccggag ccacgcaaga accgtcctcc gatcgccatt 300 gtttcaccgc agtttcagga gatttcactg ccgaccacca gtaccgttat cgatggttcg 360 cagtcaacgg atgacgacaa aatcgttcag taccactggg aagagctgaa aggcccctta 420 cgcgaagaga agatcagcga agataccgcc atcttgaaat tatcgaaact tgtgccgggt 480 aattacacgt tcagcctgac ggtggtcgat tctgatggcg caaccaactc caccaccgcc 540 aaccttaccg tcaacaaagc ggtagac 567 <210> 3 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> AAVR - Forward Primer <400> 3 aatccatggg ctctgcaggc gagtcggttc 30 <210> 4 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> AAVR - Reverse Primer <400> 4 ttactcgagt caatgatgat gatgatgatg gtctaccgct ttgttgacgg 50 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Sequence-Forward Primer <400> 5 taatacgact cactataggg 20 <210> 6 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Sequence-Reverse Primer <400> 6 atgctagtta ttgctcagcg g 21 <210> 7 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> PelB - AAVR PKD1 and PKD2 - 6His AA <400> 7 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 8 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> PelB - AAVR PKD1 and PKD2 - 6His DNA <400> 8 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 9 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.9 DNA <400> 9 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcttcgcga ctacagcggc gagatggaag gaaaacattc ccagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 10 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.9 AA <400> 10 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Leu Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 11 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.16 DNA <400> 11 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtgcaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaacagtcca aactgacgcc gggtctgtat gaattcaagg ttattgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 12 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.16 AA <400> 12 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Gln Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 13 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.29 DNA <400> 13 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtggtgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 14 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.29 AA <400> 14 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Val Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 15 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.30 DNA <400> 15 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaagggggaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaggataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 16 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.30 AA <400> 16 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Gly Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 17 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.32 (AVR2) DNA <400> 17 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 18 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.32 (AVR2) AA <400> 18 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 19 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.36 DNA <400> 19 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcctcgcga ccacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagagt 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagttccag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 20 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.36 AA <400> 20 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp His Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Ser Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 21 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.43 DNA <400> 21 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc cgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa ccaatacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagatacct ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 22 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.43 AA <400> 22 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Pro Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Asn Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ser Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 23 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.45 DNA <400> 23 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctggatgcgt atgtgctgca ggaaccaccg aaaggggaaa cccatacgta tgactggcag 180 cttattacgc atcctcgcga ctgcagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggacgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 24 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.45 AA <400> 24 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asp Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr His Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Cys Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 25 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.47 DNA <400> 25 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgtatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtgt gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaacagtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcgaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 26 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.47 AA <400> 26 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Tyr Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Cys Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Ser Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 27 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.49 DNA <400> 27 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt gtgtgctgca ggaaccaccg aaaggggaaa cctatatgta tgactggcag 180 cttattacgc atcctcgcga ctgcagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 28 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.49 AA <400> 28 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Cys Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Met Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Cys Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 29 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.53 DNA <400> 29 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctatacgta tgactggcag 180 cttattacgc atcctcgcgg ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaacagtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatggcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaggatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagcctg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 30 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.53 AA <400> 30 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Gly Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Gln Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Arg Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 31 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AVR mutant AVR3 DNA <400> 31 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 32 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR3 AA <400> 32 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 33 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> Primer I319F-F <400> 33 ccatgggctc tgcaggcgag tcggttcagt ttaccc 36 <210> 34 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AVR Mutation AVR4a AA <400> 34 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Phe 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 35 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR4a DNA <400> 35 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagtttaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 36 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer N487D R <400> 36 gattctgatg gcgcaaccga ctccaccacc 30 <210> 37 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer N487D R <400> 37 ggtggtggag tcggttgcgc catcagaatc 30 <210> 38 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR4d AA <400> 38 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 39 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR4d DNA <400> 39 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 40 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> Primer I319F-K323E-F <400> 40 ttttggtctc agttctccgg cagggtaact gaaccgac 38 <210> 41 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> Primer I319F-K323E-R <400> 41 ttttggtctc agaacgaagt acaactgaat gcgtatgtg 39 <210> 42 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR5b AA <400> 42 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Phe 20 25 30 Thr Leu Pro Glu Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Lys 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 43 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR5b DNA <400> 43 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagtttaccc tgccggagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtgaaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccaac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 44 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> Primer K399E-F <400> 44 ttttggtctc acttgcgtgg ctccggttcc acggtaacg 39 <210> 45 <211> 37 <212> DNA <213> Artificial Sequence <220> <223> Primer K399E-R <400> 45 ttttggtctc acaagaaccg tcctccgatc gccattg 37 <210> 46 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AVR Mutation AVR5e AA <400> 46 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 47 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR5e DNA <400> 47 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 48 <210> 48 <211> 56 <211> 56 <212> DNA <212> DNA <213> 人工序列(Artificial Sequence) <213> Artificial Sequence <220> <223> Indicator AVR-D2R HT1 <400> 48 atctcgagtc atccgcaggt atcgttgcgg caatgatgat gatgatgatg gtctac <210> 49 <211> 678 <212> DNA <213> Artificial Sequence <220> <223> AAVR antibody AVR5eHC DNA <400> 49 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaa cctgtacgta tgactggcag cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg aaactgtcca aactgacgcc gggtctgtat gattcaagg ttatcgttga aggtcagaat gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcattgc 660 cgcaacgata cctgcgga 678 <210> 50 <211> 226 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR5eHC AA <400> 50 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His Cys Arg Asn Asp Thr 210 215 220 Cys Gly 225 <210> 51 <211> 239 <212> PRT <213> Artificial Sequence <220> <223> Enhanced Green Fluorescent Protein AA <400> 51 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 1 5 10 15 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 20 25 30 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 35 40 45 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 50 55 60 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 65 70 75 80 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 90 95 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 100 105 110 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 115 120 125 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 130 135 140 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 145 150 155 160 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 165 170 175 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 180 185 190 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 195 200 205 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 210 215 220 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys 225 230 235 <210> 52 <211> 492 <212> DNA <213> Artificial Sequence <220> <223> Enhanced green fluorescent protein DNA <400> 52 gaattcatgg tgagcaaagg cgaggaactg tttactggtg tagtccccat actggtggaa 60 cttgatgggg atgtcaatgg tcacaaattt agcgtgtcag gagaaggcga aggagatgcg 120 acgtacggca agctgaccct taagttcatc tgtaccacgg gtaagttgcc tgttccttgg cccacacttg tgacaaccct gacctatgga gtgcaatgct tctccagata tccagaccac 240 atgaagcagc atgacttctt caaatccgcc atgccagaag gctatgtgca ggaaaggacc atcttcttta aggacgacgg aaactacaaa actcgtgctg aggtgaagtt cgaaggagac 360 acactggtga atcgaatcga gctgaaaggg attgacttta aggaggacgg gaatattctg ggccataagc tggagtacaa ctacaactct cacaatgtgt acatcatggc cgacaaacag aagaacggga ttaaggtcaa ctttaagatt cgccacaaca tcgaggatgg tagtgtacag ctcgctgacc attack gaatactccc attackgcgatg gaccagtttt gctgcctgac aaccattatc tgtcaaccca atctgccctg agcaaagatc cgaatgagaa acgggatcac 660. atggttctct tggagtttgt cacagcagca gggatcactc tcggcatgga tgagctctat 732 cc <210> 53 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.93(AVR7a) AA <400> 53 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asp Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Glu His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 54 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.93 (AVR7a) DNA <400> 54 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagga cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atccacgcga ctacagcggc gagatggaag gagaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtttgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taatgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attgtcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 55 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR Mutation No.91 (AVR7b) AA <400> 55 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Asp Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Asn Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 56 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR Mutation No.91 (AVR7b) DNA <400> 56 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggat cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca atctgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 57 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> Primer V317D-R <400> 57 ttttggtctc agcaggcgag tcggatcaga ttaccc 36 <210> 58 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> Primer V317D-F <400> 58 ttttggtctc actgcagagc ccatggccat cgccgg 36 <210> 59 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutation AVR8a AA <400> 59 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Asp Gln Ile 20 25 30 Thr Leu Pro Lys Asp Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Glu His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 60 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR8a DNA <400> 60 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggat cagattaccc tgccgaagga cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atccacgcga ctacagcggc gagatggaag gagaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtttgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taatgttacc gtggaaccgg agccacgcaa gaaccgtcct ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attgtcgaaa cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 61 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> Number K362E-R <400> 61 ttttggtctc acgagatgga aggagacat tcgcag <210> 62 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Number K362E-F <400> 62 ttttggtctc actcgccgct gtagtcgcga gg <210> 63 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR8g AA <400> 63 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Asp Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Glu His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Asn Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 64 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR8g DNA <400> 64 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggat cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctgtacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gagaacattc gcagattctg 240 aaactgtcca atctgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 65 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutant AVR10 AA <400> 65 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Asp Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Cys Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Glu His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Asn Leu Thr Pro Gly Leu Tyr Glu Phe Lys Ala Val Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 66 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR10 DNA <400> 66 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggat cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctcgacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gagaacattc gcagattctg 240 aaactgtcca atctgacgcc gggtctgtat gaattcaagg ctgtcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaactacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 67 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Primer C342S_F <400> 67 ttttggtctc agaaacctct acgtatgact g 31 <210> 68 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> Primer C342S_R <400> 68 ttttggtctc atttcccctt tcggtgg 27 <210> 69 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutation AVR10s AA <400> 69 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Asp Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Ser Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Glu His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Asn Leu Thr Pro Gly Leu Tyr Glu Phe Lys Ala Val Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp His His His His His His 210 215 <210> 70 <211> 657 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR10s DNA <400> 70 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggat cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa cctcgacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gagaacattc gcagattctg 240 aaactgtcca atctgacgcc gggtctgtat gaattcaagg ctgtcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaactacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagacc atcatcatca tcatcat 657 <210> 71 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Primer M5_F <400> 71 ttttggtctc agaaaccatg acgtatgact g 31 <210> 72 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> Primer D3_F <400> 72 ttttggtctc agatgtttgt tattttcggg ctgaacaatc 40 <210> 73 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> Primer D3_R <400> 73 ttttggtctc aagactatcc gccggtagcg aacgc 35 <210> 74 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> Primer M5D3 Vector_F <400> 74 ttttggtctc agtctaccgc tttgttg 27 <210> 75 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer M5D3 Vector_R <400> 75 ttttggtctc acatcatcat catcatcat 29 <210> 76 <211> 323 <212> PRT <213> Artificial Sequence <220> <223> AAVR mutation AVR5eMHCD3 AA <400> 76 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 1 5 10 15 Ala Gln Pro Ala Met Ala Met Gly Ser Ala Gly Glu Ser Val Gln Ile 20 25 30 Thr Leu Pro Lys Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu 35 40 45 Pro Pro Lys Gly Glu Thr Met Thr Tyr Asp Trp Gln Leu Ile Thr His 50 55 60 Pro Arg Asp Tyr Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu 65 70 75 80 Lys Leu Ser Lys Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val 85 90 95 Glu Gly Gln Asn Ala His Ser Glu Gly Tyr Val Asn Val Thr Val Glu 100 105 110 Pro Glu Pro Arg Lys Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln 115 120 125 Phe Gln Glu Ile Ser Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser 130 135 140 Gln Ser Thr Asp Asp Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu 145 150 155 160 Lys Gly Pro Leu Arg Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu 165 170 175 Lys Leu Ser Lys Leu Val Pro Gly Asn Tyr Thr Phe Arg Leu Thr Val 180 185 190 Val Asp Ser Asp Gly Ala Thr Asp Ser Thr Thr Ala Asn Leu Thr Val 195 200 205 Asn Lys Ala Val Asp Tyr Pro Pro Val Ala Asn Ala Gly Pro Asn Gln 210 215 220 Val Ile Thr Leu Pro Gln Asn Ser Ile Thr Leu Phe Gly Asn Gln Ser 225 230 235 240 Thr Asp Asp His Gly Ile Thr Ser Tyr Glu Trp Ser Leu Ser Pro Ser 245 250 255 Ser Lys Gly Lys Val Val Glu Met Gln Gly Val Arg Thr Pro Thr Leu 260 265 270 Gln Leu Ser Ala Met Gln Glu Gly Asp Tyr Thr Tyr Gln Leu Thr Val 275 280 285 Thr Asp Thr Ile Gly Gln Gln Ala Thr Ala Gln Val Thr Val Ile Val 290 295 300 Gln Pro Glu Asn Asn Lys His His His His His His Cys Arg Asn Asp 305 310 315 320 Thr Cys Gly <210> 77 <211> 969 <212> DNA <213> Artificial Sequence <220> <223> AAVR mutant AVR5eMHCD3 DNA <400> 77 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60 atggccatgg gctctgcagg cgagtcggtt cagattaccc tgccgaagaa cgaagtacaa 120 ctgaatgcgt atgtgctgca ggaaccaccg aaaggggaaa ccatgacgta tgactggcag 180 cttattacgc atcctcgcga ctacagcggc gagatggaag gaaaacattc gcagattctg 240 aaactgtcca aactgacgcc gggtctgtat gaattcaagg ttatcgttga aggtcagaat 300 gcacatagcg aaggctatgt taacgttacc gtggaaccgg agccacgcaa gaaccgtcct 360 ccgatcgcca ttgtttcacc gcagtttcag gagatttcac tgccgaccac cagtaccgtt 420 atcgatggtt cgcagtcaac ggatgacgac aaaatcgttc agtaccactg ggaagagctg 480 aaaggcccct tacgcgaaga gaagatcagc gaagataccg ccatcttgaa attatcgaaa 540 cttgtgccgg gtaattacac gttcagactg acggtggtcg attctgatgg cgcaaccgac 600 tccaccaccg ccaaccttac cgtcaacaaa gcggtagact atccgccggt agcgaacgca 660 gggccgaatc aagttattac cctccctcag aatagtatca ccctgtttgg aaatcagagc 720 acggacgatc acggcattac atcgtacgag tggagtctgt caccgtcatc gaaagggaaa 780 gtcgtggaaa tgcaaggtgt gcgtacgccc acacttcagt taagcgccat gcaggagggc 840 gattatactt accaattgac cgtaacagac actattggtc agcaggctac agcgcaagtg 900 acagtgattg ttcagcccga aaataacaaa catcatcatc atcatcattg ccgcaacgat 960 acctgcgga 969 BRIEF DESCRIPTION OF THE DRAWINGS
[0254] Figure 1 This is a graph showing the results of evaluating the binding activity of adeno-associated virus (AAV) binding protein to VLP2 (virus-like particle of AAV2) by ELISA. (+) in the graph is the result when VLP2 is fixed to a solid phase, and (-) is the result when VLP2 is not fixed to a solid phase.
[0255] Figure 2 This is a diagram showing a chromatogram of AAV2 contained in a cell lysate purified using an AVR5e column. The peak at around 20 minutes of elution time is the AAV2 elution peak, and fractions (Fr6 to 9, 1 mL each) at this peak were recovered.
[0256] Figure 3 The SDS-PAGE results show Figure 2 The AP in the figure is the analysis result of the solution diluted 100 times of the sample before purification; Fr6 to Fr9 are Figure 2 VP1 to VP3 are the positions of the bands corresponding to the three types of coat proteins constituting AAV.
[0257] Figure 4This is a diagram showing the results of recovering AAV2 contained in a solution using a column filled with a wild-type AAV binding protein (Wild type) immobilized gel or an AVR5eHC immobilized gel.
[0258] Figure 5 The graph shows the results of recovering AAV2 contained in a solution using a column filled with a wild-type AAV binding protein (Wild type) immobilized gel, AVR3HC immobilized gel, or AVR8gHC immobilized gel. Example
[0259] Examples are shown below for further explaining the present invention in detail, but the present invention is not limited to these examples.
[0260] Example 1 Preparation of adeno-associated virus (AAV) binding protein expression vector
[0261] (1) The codons of the nucleotide sequence encoding the amino acid residues from serine (Ser) at position 312 to aspartic acid (Asp) at position 500 of the extracellular domains 1 and 2 (PKD1 and PKD2) in the amino acid sequence of the AAV binding protein described in SEQ ID NO: 1 (UniProt accession number: Q8IZA0) were converted from the human type to the E. coli type. The nucleotide sequence after the codon conversion is shown in SEQ ID NO: 2.
[0262] (2) The gene described in sequence number 2 was artificially synthesized and cloned into a plasmid (commissioned to Eurofins Genomics K.K.). The prepared plasmid was named pUC-AAVR, and PCR was performed using the plasmid as a template and oligonucleotides consisting of the sequences described in sequence number 3 (5'-AAT[CCATGG]GCTCTGCAGGCGAGTCGGTTC-3') and sequence number 4 (5'-TTA[CTCGAG]TCAATGATGATGATGATGATGGTCTACCGCTTTGTTGACGG-3') as PCR primers (the square brackets in sequence number 3 represent the recognition sequence of the restriction endonuclease NcoI, and the square brackets in sequence number 4 represent the recognition sequence of the restriction endonuclease XhoI, respectively). Specifically, a reaction solution of the composition shown in Table 1 was prepared, and after heat treatment of the reaction solution at 98°C for 5 minutes, a reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 90 seconds was repeated 30 cycles.
[0263] [Table 1]
[0264] composition volume Template DNA (10 ng / μL) 1μL 10 μM PCR primer (SEQ ID NO: 3, 33) 2μL 10 μM PCR primer (SEQ ID NO. 4) 2μL 5× PrimeSTAR buffer (manufactured by Takara Bio Inc.) 10μL 2.5mM dNTPs 4μL 2.5U / μL PrimeSTAR HS (manufactured by Takara Bio Inc.) 1μL <![CDATA[H2O]]> Make up to 50 μL
[0265] (3) The polynucleotide obtained in (2) was purified, digested with restriction endonucleases NcoI and XhoI, and then ligated with expression vector pET26b (manufactured by MERCK MILLIPORE) that had been previously digested with restriction endonucleases NcoI and XhoI. The ligated product was used to transform Escherichia coli BL21 strain (DE3).
[0266] (4) The transformant obtained in (3) was cultured in LB (Luria-Bertani) medium containing 50 μg / mL kanamycin, and then the vector pET-AAVRD2 expressing the extracellular domain 1 and domain 2 of the AAV binding protein was extracted using the QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0267] (5) The nucleotide sequence of the polynucleotide encoding the AAV binding protein and its surrounding region in the expression vector pET-AAVRD2 prepared in (4) was analyzed using a fully automatic DNA sequencer Genetic Analyzer 3500 (manufactured by Thermo Fisher Scientific). It should be noted that when performing this analysis, an oligonucleotide consisting of the sequence described in sequence number 5 (5'-TAATACGACTCACTATAGGG-3') or sequence number 6 (5'-ATGCTAGTTATTGCTCAGCGG-3') was used as a sequencing primer.
[0268] Separately, the amino acid sequence of the polypeptide expressed by the expression vector pET-AAVRD2 is shown in sequence number 7, and the sequence of the polynucleotide encoding the peptide is shown in sequence number 8. It should be noted that in sequence number 7, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide, the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the extracellular region of the AAV binding protein (domain 1 and domain 2, the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence.
[0269] Example 2 Expression of AAV-binding protein and evaluation of binding to AAV
[0270] (1) The Escherichia coli strain BL21 (DE3) transformed with pET-AAVRD2 prepared in Example 1 was inoculated into 3 mL of 2YT liquid medium (16 g / L peptone, 10 g / L yeast extract, 5 g / L sodium chloride) containing 50 μg / mL kanamycin, and cultured at 37°C with aerobic shaking overnight to perform pre-culture.
[0271] (2) 200 μL of the preculture solution of (1) was inoculated into 20 mL of 2YT liquid medium supplemented with 50 μg / mL kanamycin in a 100 mL baffled flask, and cultured aerobically at 37°C.
[0272] (3) 2.0 hours after the start of the culture, the cells were cooled on ice, IPTG (Isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 0.1 mM, and then cultured overnight at 25°C with aerobic shaking.
[0273] (4) After the culture was completed, 2 mL of the culture solution was collected and centrifuged to collect the bacteria. The obtained bacteria were used with 200 μL of BugBuster Protein extraction kit (Merck Millipore) to prepare a protein extract containing the expressed AAV binding protein. The prepared protein extract was diluted 30 times with 20 mM Tris hydrochloric acid buffer (pH 7.4) containing 150 mM sodium chloride.
[0274] (5) Preparation of VLP2 (AAV2 virus-like particles)
[0275] (5-1) Escherichia coli JM109 strain was transformed using pRC2-mi342 Vector (manufactured by Takara Bio Inc.) and pHelper Vector (manufactured by Takara Bio Inc.). The obtained transformants were cultured with shaking overnight at 37°C in 5 L baffled flasks containing 1 L of 2YT medium to which carbenicillin was added at a concentration of 100 μg / mL.
[0276] (5-2) The culture solution of (5-1) was centrifuged to recover the bacterial cells. From the obtained bacterial cells, pRC2-mi342 Vector and pHelper Vector were prepared in large quantities using Plasmid Mega Kit (manufactured by QIAGEN).
[0277] (5-3) HEK293T cells were cultured in five T-225 flasks (manufactured by Thermo Fisher Scientific) in 40 mL of D-MEM medium (manufactured by FUJIFILM Wako Pure Chemical Corporation) containing 10% (v / v) bovine serum. Genes were introduced into the pRC2-mi342 Vector and pHelper Vector prepared in (5-2) using TransIT-ViruGEN Transfection Reagent (manufactured by TakaraBio Inc.), and the cells were statically cultured for 3 days under the conditions of 5% carbon dioxide and 37°C.
[0278] (5-4) The cultured cells of (5-3) were collected, extracted and purified using AAVpro Purification Kit (manufactured by Takara Bio Inc.) to obtain VLP2. About 1 mL of the purified VLP2 solution was prepared from five T-225 flasks.
[0279] (6) The binding ability of the AAV binding protein in the protein extract prepared in (4) to the VLP2 prepared in (5) was evaluated by ELISA.
[0280] (6-1) The VLP2 prepared in (5) was diluted 200-fold to 1000-fold with 20 mM Tris hydrochloric acid buffer (pH 7.4) containing 150 mM sodium chloride, and added to a 96-well microplate (manufactured by Thermo Fisher Scientific) at 100 μL / well for fixation (18 hours at 4°C). After fixation, the plate was blocked with 20 mM Tris hydrochloric acid buffer (pH 7.4) containing 2% (w / v) skim milk (manufactured by Becton Dickinson) and 150 mM sodium chloride.
[0281] (6-2) After washing with a washing buffer (containing 0.05% [w / v] Tween 20 (trade name), 150 mM sodium chloride in 20 mM Tris-HCl buffer (pH 7.4)), a solution containing AAV binding protein for evaluating VLP2 binding activity is added to allow the AAV binding protein to react with VLP2 (at 30°C for 1 hour).
[0282] (6-3) After the reaction was completed, the cells were washed with the washing buffer, and 100 μL / well of Anti-6His antibody (Bethyl Laboratories) diluted to 100 ng / mL was added.
[0283] (6-4) After reacting at 30°C for 1 hour and washing with the washing buffer, 50 μL / well of TMB peroxidase substrate (manufactured by KPL) was added. 50 μL / well of 1 M phosphoric acid was added to stop color development, and the absorbance at 450 nm was measured using a microplate reader (manufactured by Tecan).
[0284] The results of ELISA are shown in Figure 1 . When VLP2 is fixed to a solid phase (VLP(+)), a high absorbance is shown, so it can be known that the AAV binding protein expressed in this example binds to VLP2. It should be noted that VLP2 is a virus-like particle of AAV2, so it can be said that this result is synonymous with the result that the AAV binding protein binds to AAV2.
[0285] Example 3 Preparation and Screening of Mutant Library of AAV Binding Protein (Part 1)
[0286] Random mutations were introduced into the polynucleotide portion encoding the AAV binding protein in the AAV binding protein expression vector pET-AAVRD2 by error-prone PCR.
[0287] (1) Error-prone PCR was performed using pET-AAVRD2 prepared in Example 1 as a template. Error-prone PCR was performed as follows: After preparing a reaction solution of the composition shown in Table 2, the reaction solution was heat-treated at 98°C for 2 minutes, and 30 cycles of a first step at 98°C for 30 seconds, a second step at 55°C for 20 seconds, and a third step at 72°C for 90 seconds were performed as one cycle, and finally heat-treated at 72°C for 5 minutes. Mutations were well introduced into the polynucleotide encoding the AAV binding protein by the error-prone PCR, and the average mutation introduction rate was 1.8 amino acid mutations per molecule.
[0288] [Table 2]
[0289] composition volume Template DNA (pET-AAVRD2) 10 ng / μL 1μL 10 μM PCR primer (SEQ ID NO. 3) 2μL 10 μM PCR primer (SEQ ID NO. 4) 2μL <![CDATA[10mM MnCl2]]> 1.5μL 2.5mM dNTPs 4μL 10×Ex Taq buffer (manufactured by Takara Bio Inc.) 5μL GoTaq polymerase (manufactured by Promega Corporation) 0.5μL <![CDATA[H2O]]> Make up to 50 μL
[0290] (2) The PCR product obtained in (1) was purified, digested with restriction endonucleases NcoI and XhoI, and ligated with the expression vector pET26b (manufactured by MERCK MILLIPORE) that had been digested in advance with the same restriction endonucleases.
[0291] (3) After the ligation reaction, the reaction solution was used to transform Escherichia coli BL21 (DE3), and the cells were cultured on LB plates containing 50 μg / mL kanamycin (at 37°C for 18 hours). The colonies formed on the plates were used as a random mutant library.
[0292] (4) The random mutant library (transformants) prepared in (3) was inoculated into 200 μL of 2YT liquid medium containing 50 μg / mL kanamycin, and cultured with shaking at 37°C overnight using a 96-well deep-well plate.
[0293] (5) 10 μL of the culture solution prepared in (4) was transplanted into 500 μL of 2YT liquid medium containing 0.1 mM IPTG and 50 μg / mL kanamycin, and further cultured with shaking at 25°C overnight using a 96-well deep-well plate.
[0294] (6) The culture solution of (5) was centrifuged and the obtained culture supernatant was diluted 2-fold with 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride. The diluted solution was heat-treated at 43°C for 15 minutes.
[0295] (7) The binding activity of the AAV binding protein to VLP2 when the heat treatment of (6) was performed and the binding activity of the AAV binding protein to VLP2 when the heat treatment of (6) was not performed were measured using the ELISA method described in (6) of Example 2, and the binding activity of the AAV binding protein to VLP2 when the heat treatment was performed was divided by the binding activity of the AAV binding protein to VLP2 when the heat treatment was not performed, thereby calculating the residual activity.
[0296] (8) About 2700 transformants were evaluated by the method of (7), and transformants expressing AAV binding proteins with improved thermal stability compared with wild-type (no amino acid substitution) AAV binding proteins were selected. The selected transformants were cultured and expression vectors were prepared using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0297] (9) The nucleotide sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed by the same method as described in (5) of Example 1 to determine the amino acid mutation site.
[0298] The amino acid substitution positions of the AAV binding proteins expressed by the transformants selected in (8) above relative to the wild-type (no amino acid substitution) AAV binding proteins and the residual activity (%) after heat treatment are summarized and shown in Table 3.It can be said that in the amino acid sequence recorded in SEQ ID NO: 1, Ile319Phe (this mark indicates that the isoleucine at position 319 of SEQ ID NO: 1 is substituted with phenylalanine, and the same applies hereinafter), Leu321Pro, Pro322Leu, Asn324Asp, Asn324Ser, Gln327Arg, Asn329Asp, Asn329Tyr, Ala330Gly, Tyr331Cys, Val332Gln, Leu333Val, Leu333Pro, Gln334Arg, Pro337 Leu, Lys338Arg, Lys338Glu, Glu340Gly, Thr341Ala, Tyr342Cys, Tyr342His, Tyr342Asn, Thr343Met, Tyr344His, Asp345Asn, Trp346Leu, Trp346Ar g, Gln347Leu, Gln347Pro, Leu348Pro, Ile349Thr, Thr350Met, His351Leu, Pro352Leu, Arg353Cys, Asp354Gly, Tyr355His, Tyr355Asn, Tyr355Cys, Ser356Cys, Gly357Cys, His363Arg, His363Leu, Ser364Pro, Gln365Arg, Ile366Thr, Leu367Pro, Lys368Arg, Leu369Gln, Leu369Pro, Ser370Ala, L ys371Glu, Thr373Ala, Leu376Pro, Tyr377Cys, Phe379Ser, Val381Ala, Glu384Gly, Asn387Ser, His389Gln, His389Leu, His389Arg, Gly390Ser, Glu An AAV-binding protein having at least one of any amino acid substitutions of 391Lys, Tyr393Cys, Val396Ala, Lys399Glu, Lys399Arg, Arg406Ser, Val412Ala, Gln415Leu, Phe416Ser, Gln441Leu, Tyr442Phe, Lys448Arg, Glu453Gly, Lys455Arg, Glu458Gly, Ala461Ser, Ser476Arg, Leu477Pro, Asn487Asp and Asn492Asp has improved thermal stability compared to the wild-type AAV-binding protein.
[0299] [Table 3]
[0300]
[0301] Example 4 Evaluation of thermal stability of AAV binding protein mutants (amino acid substitutions)
[0302] From the AAV binding proteins with amino acid substitutions (mutants) shown in Table 3, No. 9 (Pro352Leu substitution), No. 16 (Leu369Gln substitution), No. 29 (Leu333Val and Tyr342Cys substitution), No. 30 (Glu340Gly and Tyr342Cys substitution), No. 32 (Tyr342Cys and Gly390Ser substitution), No. 36 (Tyr355His and Asn387Ser substitution), No. 43 (Leu3 21Pro, Tyr342Asn and Ala461Ser substitution body), No.45 (Asn329Asp, Tyr342His and Tyr355Cys substitution body), No.47 (Asn329Tyr, Tyr377Cys and Arg406Ser substitution body), No.49 (Tyr331Cys, Thr343Met and Tyr355Cys substitution body) and No.53 (Asp354Gly, Leu369Gln and Lys455Arg substitution body), and the thermal stability was re-evaluated.
[0303] It should be noted that the nucleotide sequence and amino acid sequence of No. 9 are shown in SEQ ID NOs. 9 and 10, respectively.
[0304] The nucleotide sequence and amino acid sequence of No.16 are shown in SEQ ID NOs: 11 and 12.
[0305] The nucleotide sequence and amino acid sequence of No.29 are shown in SEQ ID NOs: 13 and 14.
[0306] The nucleotide sequence and amino acid sequence of No.30 are shown in SEQ ID NOs: 15 and 16.
[0307] The nucleotide sequence and amino acid sequence of No.32 are shown in SEQ ID NOs: 17 and 18.
[0308] The nucleotide sequence and amino acid sequence of No.36 are shown in SEQ ID NOs: 19 and 20.
[0309] The nucleotide sequence and amino acid sequence of No.43 are shown in SEQ ID NOs: 21 and 22.
[0310] The nucleotide sequence and amino acid sequence of No.45 are shown in SEQ ID NOs: 23 and 24.
[0311] The nucleotide sequence and amino acid sequence of No.47 are shown in SEQ ID NOs: 25 and 26.
[0312] The nucleotide sequence and amino acid sequence of No.49 are shown in SEQ ID NOs: 27 and 28.
[0313] The nucleotide sequence and amino acid sequence of No. 53 are shown in SEQ ID NOs: 29 and 30.
[0314] In addition, the substitution of Pro352Leu in the amino acid sequence of No. 9 (SEQ ID NO: 10) is located at position 65 in SEQ ID NO: 10.
[0315] The substitution of Leu369Gln in the amino acid sequence of No.16 (SEQ ID NO.12) is located at position 82 in SEQ ID NO.12.
[0316] The substitutions of Leu333Val and Tyr342Cys in the amino acid sequence of No. 29 (SEQ ID NO: 14) are located at positions 46 and 55 in SEQ ID NO: 14.
[0317] The substitutions of Glu340Gly and Tyr342Cys in the amino acid sequence of No.30 (SEQ ID NO: 16) are located at positions 53 and 55 in SEQ ID NO: 16.
[0318] The substitutions of Tyr342Cys and Gly390Ser in the amino acid sequence of No.32 (SEQ ID NO: 18) are located at positions 55 and 103 in SEQ ID NO: 18,
[0319] The substitutions of Tyr355His and Asn387Ser in the amino acid sequence of No.36 (SEQ ID NO: 20) are located at positions 68 and 100 in SEQ ID NO: 20,
[0320] The substitutions of Leu321Pro, Tyr342Asn and Ala461Ser in the amino acid sequence of No. 43 (SEQ ID NO: 22) are located at positions 34, 55 and 174, respectively, in SEQ ID NO: 22.
[0321] The substitutions of Asn329Asp, Tyr342His and Tyr355Cys in the amino acid sequence of No.45 (SEQ ID NO: 24) are located at positions 42, 55 and 68, respectively, in SEQ ID NO: 24.
[0322] The substitutions of Asn329Tyr, Tyr377Cys and Arg406Ser in the amino acid sequence of No.47 (SEQ ID NO: 26) are located at positions 42, 90 and 119, respectively, in SEQ ID NO: 26.
[0323] The substitutions of Tyr331Cys, Thr343Met, and Tyr355Cys in the amino acid sequence of No. 49 (SEQ ID NO: 28) are located at positions 44, 56, and 68, respectively, in SEQ ID NO: 30.
[0324] The substitutions of Asp354Gly, Leu369Gln, and Lys455Arg in the amino acid sequence of No. 53 (SEQ ID NO: 30) are located at positions 67, 82, and 168 in SEQ ID NO: 28.
[0325] (1) After culturing the transformants expressing the 11 selected mutant AAV binding proteins and the transformants expressing the wild-type AAV binding protein obtained in (3) of Example 1 by the methods described in (4) and (5) of Example 3, the culture fluid is centrifuged to obtain culture supernatants containing the expressed mutant AAV binding proteins and wild-type AAV binding proteins, respectively.
[0326] (2) The binding activity of the AAV binding protein and VLP2 in the culture supernatant obtained in (1) was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the culture supernatant obtained in (1) was diluted with 20 mM Tris buffer (pH 7.4) containing 150 mM sodium chloride so that the measurement value was the same.
[0327] (3) The diluted protein solution was divided into three portions, two of which were heat-treated at 50.3°C or 66.1°C for 15 minutes using a Thermal Cycler (manufactured by Eppendorf SE), and the remaining portion was not heat-treated.
[0328] (4) The binding activity of the AAV binding activity protein to VLP2 after the heat treatment of (3) or without heat treatment is measured by the ELISA method described in (6) of Example 2, and the absorbance at 450 nm after heat treatment is divided by the absorbance at 450 nm without heat treatment to calculate the residual activity.
[0329] The results are shown in Table 4. It was confirmed that all the mutant AAV binding proteins had higher residual activities than the wild-type AAV binding protein, and that the thermal stability of the mutant AAV binding proteins was improved.
[0330] [Table 4]
[0331]
[0332] Example 5 Evaluation of Acid Stability of Mutant AAV Binding Proteins (Part 1)
[0333] (1) The transformants expressing mutant AAV binding proteins evaluated in Example 4 (i.e., mutant AAV binding proteins described in No. 9, No. 16, No. 29, No. 30, No. 32, No. 36, No. 43, No. 45, No. 47, No. 49 and No. 53 in Table 3) and the transformants expressing wild-type AAV binding proteins obtained in (3) of Example 1 were cultured by the methods described in (4) and (5) of Example 3, respectively, and the culture fluids were centrifuged to obtain culture supernatants containing the expressed mutant AAV binding proteins or wild-type AAV binding proteins.
[0334] (2) The binding activity of the AAV binding protein and VLP2 in the culture supernatant obtained in (1) was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the culture supernatant obtained in (1) was diluted with pure water so that the measurement value became the same.
[0335] (3) The diluted protein solution was divided into two parts, and an equal amount of 0.1M glycine hydrochloride buffer (pH2.5) was mixed into one part. After standing at 30°C for 2 hours and 24 hours, it was mixed with 0.5M MES buffer (pH6.0) at a ratio of 3:2 to adjust the pH to around 6, and the binding activity with VLP2 was measured by the ELISA method described in (6) of Example 2. The other part was not subjected to the acid treatment, and after the dilution ratio was made the same as the acid treatment conditions, it was mixed with 0.5M MES buffer (pH6.0) at a ratio of 3:2 to adjust the pH to around 6, and the binding activity with VLP2 was measured by the ELISA method described in (6) of Example 2.
[0336] (4) The residual activity was calculated by dividing the absorbance at 450 nm when the acid treatment described in (3) was performed by the absorbance at 450 nm when the acid treatment was not performed.
[0337] The results are shown in Table 5. Among all the mutant AAV binding proteins evaluated in Example 4, the residual activity after treatment for 2 hours and 24 hours at 30°C and pH 2.5 was improved compared with the wild type. In other words, it can be confirmed that the acid stability of the mutant AAV binding proteins is improved. Among them, No. 30 (Glu340Gly and Tyr342Cys substitution, sequence number 16), No. 32 (Tyr342Cys and Gly390Ser substitution, sequence number 18) and No. 45 (Asn329Asp, Tyr342His and Tyr355Cys substitution, sequence number 24) have significantly improved acid stability compared with the wild-type AAV binding protein.
[0338] [Table 5]
[0339]
[0340] Example 6 Preparation and Screening of Mutant Library of AAV Binding Protein (Part 2)
[0341] No. 32 (Tyr342Cys and Gly390Ser substitution; sequence number 18) (named AVR2) among the mutant AAV binding proteins evaluated in Examples 4 and 5 was selected, and random mutations were introduced into the polynucleotide portion encoding the protein by error-prone PCR.
[0342] (1) Using plasmid pET-AVR2 inserted with a polynucleotide (SEQ ID NO: 17) encoding AVR2 (SEQ ID NO: 18) as a template, a reaction solution of the composition shown in Table 6 was prepared, and then error-prone PCR was performed under the same temperature conditions as in (1) of Example 3. By the error-prone PCR, mutations were introduced into the polynucleotide encoding AVR2 at an average mutation rate of 1.5 amino acid mutations per molecule.
[0343] [Table 6]
[0344] composition volume 10ng / μL template DNA 1μL 10 μM PCR primer (SEQ ID NO. 3) 2μL 10 μM PCR primer (SEQ ID NO. 4) 2μL <![CDATA[10mM MnCl2]]> 0.5μL 2.5mM dNTPs 4μL 10×Ex Taq buffer (manufactured by Takara Bio Inc.) 5μL GoTaq polymerase (manufactured by Promega Corporation) 0.5μL <![CDATA[H2O]]> Make up to 50 μL
[0345] (2) The PCR product obtained in (1) was purified, digested with restriction endonucleases NcoI and XhoI, and ligated with the expression vector pET26b (manufactured by MERCK MILLIPORE) that had been digested in advance with the same restriction endonucleases.
[0346] (3) After the ligation reaction, the reaction solution was used to transform Escherichia coli BL21 (DE3), and the cells were cultured on LB plates containing 50 μg / mL kanamycin (at 37°C overnight). The colonies formed on the plates were used as a random mutant library.
[0347] (4) The random mutant library (transformants) prepared in (3) was cultured by the methods described in (4) and (5) of Example 3.
[0348] (5) The culture solution of (4) was centrifuged and the obtained culture supernatant was diluted 4 times with ultrapure water. 60 μL of the diluted culture solution was mixed with 60 μL of 0.1 M glycine hydrochloride buffer (pH 3.0), and heat and acid treated at 51.1°C for 15 minutes.
[0349] (6) The binding activity of the AAV binding protein to VLP2 when subjected to the treatment of (5) and the binding activity of the AAV binding protein to VLP2 when not subjected to the treatment of (5) were measured using the ELISA method described in (6) of Example 2. The residual activity was calculated by dividing the binding activity of the AAV binding protein to VLP2 when subjected to heat treatment by the binding activity of the AAV binding protein to VLP2 when not subjected to heat treatment.
[0350] (7) The random mutant library of about 1,800 strains was evaluated using the method of (6), and transformants expressing AAV binding proteins with improved residual activity compared to AVR2 as the parent molecule were selected. The selected transformants were cultured and expression vectors were prepared using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0351] (8) The nucleotide sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed by the method described in (5) of Example 1 to determine the amino acid mutation site.
[0352] The amino acid substitution sites of the AAV binding proteins expressed by the transformants selected in (7) relative to AVR2 (Tyr342Cys and Gly390Ser substitutions) and the residual activities (%) after heat and acid treatment are summarized and shown in Table 7.
[0353] In the amino acid sequence described in SEQ ID NO: 1, Ile319Phe, Ile319Asn, Ile319Ser, Thr320Ile, Leu321Pro, Lys323Glu, Leu328Gln, Leu328Pro, Tyr331His, Val332Ala, Val332Glu, Leu333Pro, Pro336Gln, Pro337Gln, Lys338Asn, Tyr(Cys)342Arg (this mark indicates that the tyrosine at position 342 of SEQ ID NO: 1 is temporarily replaced by It can be said that the AAV binding protein in which at least one of the amino acid substitutions of Thr350Ser, Gln365Arg, Ile366Phe, Phe379Ser, Val383Ala, Gln386Arg, His389Asp, Gly392Cys, Val394Ala, Val396Ala, Lys399Glu, Ile409Val, Ser476Gly, Ser476Arg, Asn487Asp, Thr490Ser and Asn492Asp is substituted has improved stability to heat and acid compared to the wild-type AAV binding protein.
[0354] [Table 7]
[0355] No. Amino acid substitution Residual activity [%] No. Amino acid substitution Residual activity [%] 58 Ile319Phe 73.9 71 His389ASp 71.9 59 Ile319Asn 26.1 72 Val394Ala 32.0 60 Lys323Glu 80.2 73 Va1396Ala 48.9 61 Leu328Gln 43.5 74 Ser476Gly 63.4 62 Leu328Pro 38.8 75 Ser476Arg 96.3 63 Tyr331His 43.1 76 Asn492Asp 36.4 64 Val332Ala 41.4 77 Leu321Pro, Ile409Val 34.3 65 Val332Glu 29.4 78 Leu328Pro, Ile366Phe 55.9 66 Leu333Pro 31.8 79 Lys338Asn,Asn487Asp 73.1 67 Pro337Gln 45.6 80 Gln365Arg, Gly392Cys 49.9 68 Tyr(Cys)342Arg 70.4 81 Phc379Scr,Scr476Gly 66.3 69 Thr350Ser 49.9 82 Ser476Arg, Thr490Ser 70.6 70 Val383Ala 32.8 83 Ile319Ser, Thr320Ile.Lys399Glu 70.2 32 AVR2 25.5 84 Pro336Gln,GIn386Arg.Asn487Asp 48.4
[0356] Example 7 Integration of stabilizing amino acid substitutions (Part 1)
[0357] The amino acid substitution associated with the improved heat and acid stability of the AAV binding protein determined in Example 6 was integrated into AVR2 (sequence number 18) to seek further stability improvement. Specifically, No. 75 (amino acid substitution of Ser476Arg integrated into AVR2) (named AVR3) among the (mutant) AAV binding proteins with amino acid substitutions shown in Table 7 was selected, and the amino acid substitution shown in any one of the following (a) to (d) was integrated into the protein. It should be noted that the substitution of Ser476Arg in the amino acid sequence of AVR3 (sequence number 32) is located at position 189 in sequence number 32.
[0358] (a) Ile319Phe (named AVR4a)
[0359] (b) Asn487Asp (named AVR4d)
[0360] (c) Ile319Phe and Lys323Glu (named AVR5b)
[0361] (d) Lys399Glu and Asn487Asp (named AVR5e)
[0362] Hereinafter, methods for producing each AAV-binding protein will be described in detail.
[0363] (a) AVR4a
[0364] From the amino acid substitutions related to improved stability to heat and acid identified in Example 6, Ile319Phe was selected and integrated into AVR3 (SEQ ID NO: 32) to produce AVR4a. Specifically, a mutation causing Ile319Phe was introduced into a polynucleotide (SEQ ID NO: 31) encoding AVR3 (SEQ ID NO: 32) to produce AVR4a.
[0365] (a-1) Plasmid pET-AVR3 into which a polynucleotide encoding AVR3 (SEQ ID NO: 31) was inserted was used as a template, and oligonucleotides consisting of the sequences described in SEQ ID NO: 4 and SEQ ID NO: 33 (5'-CCATGGGCTCTGCAGGCGAGTCGGTTCAGTTTACCC-3') were used as PCR primers to prepare a reaction solution of the composition shown in Table 1. The reaction solution was heat-treated at 98°C for 5 minutes, and a reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 1 minute as one cycle was performed for 30 cycles, and finally heat-treated at 72°C for 5 minutes to perform PCR.
[0366] (a-2) The amplified PCR product was subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction Kit (manufactured by QIAGEN). The purified PCR product was named 4ap.
[0367] (a-3) After purifying 4ap obtained in (a-2), it was digested with restriction endonucleases NcoI and XhoI, ligated with expression vector pET26b (manufactured by MERCKMILLIPORE) that had been previously digested with restriction endonucleases NcoI and XhoI, and the ligated product was used to transform Escherichia coli BL21 strain (DE3).
[0368] (a-4) The transformant obtained in (a-3) was cultured in LB medium supplemented with 50 μg / mL kanamycin. A plasmid was extracted from the recovered bacterial cells (transformant) to obtain a plasmid pET-AVR4a containing a polynucleotide encoding AVR4a, wherein the AVR4a had 4 amino acid substitutions relative to the wild-type AAV binding protein.
[0369] (a-5) The nucleotide sequence of pET-AVR4a was analyzed by the same method as in Example 1 (5).
[0370] Sequentially, the amino acid sequence of AVR4a to which a signal sequence and a polyhistidine tag are added is shown in sequence number 34; the sequence of the polynucleotide encoding the AVR4a is shown in sequence number 35. It should be noted that in sequence number 34, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR4a (domain 1 and domain 2, corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In SEQ ID NO: 34, phenylalanine of Ile319Phe is present at position 32, cysteine of Tyr342Cys is present at position 55, serine of Gly390Ser is present at position 103, and arginine of Ser476Arg is present at position 189.
[0371] (b)AVR4d
[0372] From the amino acid substitutions related to improved stability to heat and acid identified in Example 6, Asn487Asp was selected and incorporated into AVR3 (SEQ ID NO: 32) to produce AVR4d. Specifically, AVR4d was produced by introducing a mutation that produces Asn487Asp into a polynucleotide (SEQ ID NO: 31) encoding AVR3 (SEQ ID NO: 32).
[0373] (b-1) Using pET-AVR3 as a template and oligonucleotides consisting of the sequences described in SEQ ID NOs. 5 and 36 (5'-GATTCTGATGGCGCAACCGACTCCACCACC-3') as PCR primers, a reaction solution of the composition shown in Table 8 was prepared. The reaction solution was heat-treated at 98°C for 5 minutes, and 30 cycles of a reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 1 minute as one cycle were performed, and finally heat-treated at 72°C for 5 minutes to perform PCR.
[0374] [Table 8]
[0375] composition volume 10ng / μL template DNA 1μL 10 μM PCR primers (SEQ ID NOs. 5, 37, 40, 44) 1μL 10 μM PCR primers (SEQ ID NOs. 36, 6, 41, 45) 1μL 5× PrimeSIAR buffer (manufactured by Takara Bio Inc.) 10μL 2.5mM dNTPs 4μL 2.5 U / μL PrimeST AR HS (manufactured by Takara Bio Inc.) 1μL <![CDATA[H2O]]> Make up to 50 μL
[0376] (b-2) The amplified PCR product was purified by the same method as in (a-2). The purified PCR product was named 4dF.
[0377] (b-3) PCR was performed in the same manner as (b-1) and (b-2) except that pET-AVR3 was used as a template and oligonucleotides consisting of the sequences described in SEQ ID NO: 6 and SEQ ID NO: 37 (5'-GGTGGTGGAGTCGGTTGCGCCATCAGAATC-3') were used as PCR primers. The purified PCR product was named 4dR.
[0378] (b-4) After mixing the two PCR products (4dF, 4dR) obtained in (b-2) and (b-3), a reaction solution with the composition shown in Table 9 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. Then, PCR was performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 1 minute as one cycle to obtain a PCR product 4dp formed by connecting 4dF and 4dR.
[0379] [Table 9]
[0380] composition volume PCR product (4dF) 1μL PGR product (4dR) 1μL 10 μM PCR primer (SEQ ID NO: 5) 1μL 10 μM PCR primer (SEQ ID NO: 6) 1μL 5× PrimeSTAR buffer (manufactured by Takara Bio Inc.) 10μL 2.5mM dNTPs 4μL 2.5U / μL PrimeSTAR HS (manufactured by Takara Bio Inc.) 1μL <![CDATA[H2O]]> Make up to 50 μL
[0381] (b-5) The PCR product 4dp obtained in (b-4) is treated in the same manner as (a-3) and (a-4) to obtain a plasmid pET-AVR4d containing a polynucleotide encoding AVR4d, wherein AVR4d has undergone 4-site amino acid substitutions relative to the wild-type AAV binding protein.
[0382] (b-6) The nucleotide sequence of pET-AVR4d was analyzed by the same method as in Example 1 (5).
[0383] Sequentially, the amino acid sequence of AVR4d to which a signal sequence and a polyhistidine tag are added is shown in sequence number 38; the sequence of the polynucleotide encoding the AVR4d is shown in sequence number 39. It should be noted that in sequence number 38, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR4d (corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In SEQ ID NO: 38, cysteine of Tyr342Cys is present at position 55, serine of Gly390Ser is present at position 103, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0384] (c)AVR5b
[0385] From the amino acid substitutions related to improved stability to heat and acid identified in Example 6, Ile319Phe and Lys323Glu were selected and incorporated into AVR3 (SEQ ID NO: 32) to produce AVR5b. Specifically, mutations producing Ile319Phe and Lys323Glu were introduced into the polynucleotide (SEQ ID NO: 31) encoding AVR3 (SEQ ID NO: 32) to produce AVR5b.
[0386] (c-1) Using pET-AVR3 as a template and oligonucleotides consisting of the sequences described in SEQ ID NO: 40 (5'-TTTT[GGTCTC]AGTTCTCCGGCAGGGTAACTGAACCGAC-3') and SEQ ID NO: 41 (5'-TTTT[GGTCTC]AGAACGAAGTACAACTGAATGCGTATGTG-3') as PCR primers (the square brackets in SEQ ID NOs. 40 and 41 represent the recognition sequence of the restriction endonuclease BsaI), a reaction solution of the composition shown in Table 8 was prepared. The reaction solution was heat-treated at 98°C for 5 minutes, and PCR was performed for 30 cycles with a first step of 10 seconds at 98°C, a second step of 55°C for 5 seconds, and a third step of 6 minutes at 72°C as one cycle, and finally heat-treated at 72°C for 5 minutes.
[0387] (c-2) The amplified PCR product was purified in the same manner as in (a-2). The purified PCR product was named 5bp.
[0388] (c-3) The 5 bp obtained in (c-2) was treated with restriction endonuclease DpnI (manufactured by NEB) at 37°C for 1.5 hours. Thereafter, the gene was subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction kit (manufactured by QIAGEN).
[0389] (c-4) The DpnI-treated product obtained in (c-3) was digested with restriction endonuclease BsaI (manufactured by NEB) in a reaction solution having the composition shown in Table 10 and ligated with T4 DNA ligase (manufactured by NEB).
[0390] [Table 10]
[0391] composition volume PCR product (20ng / μL) 5μL 10× CutSmart Buffer (NEB) 1.5μL Bsal (manufactured by NEB) 1μL T4 DNA ligase buffer (manufactured by NEB) 1.5μL T4 DNA ligase (NEB) 1μL <![CDATA[H2O]]> Make up to 15 μL
[0392] (c-5) The ligation product of (c-4) was used to transform Escherichia coli BL21 strain (DE3). The obtained transformant was cultured in LB medium supplemented with 50 μg / mL of kanamycin. The plasmid was extracted from the recovered bacteria (transformant) to obtain a plasmid pET-AVR5b containing a polynucleotide encoding AVR5b, wherein the AVR5b was subjected to amino acid substitutions at 5 positions relative to the wild-type AAV binding protein.
[0393] (c-6) The nucleotide sequence of pET-AVR5b was analyzed by the same method as in Example 1 (5).
[0394] Sequentially, the amino acid sequence of AVR5b to which a signal sequence and a polyhistidine tag are added is shown in sequence number 42; the sequence of the polynucleotide encoding the AVR5b is shown in sequence number 43. It should be noted that in sequence number 42, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR5b (corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In addition, in sequence number 42, phenylalanine of Ile319Phe is present at position 32, glutamic acid of Lys323Glu is present at position 36, cysteine of Tyr342Cys is present at position 55, serine of Gly390Ser is present at position 103, and arginine of Ser476Arg is present at position 189.
[0395] (d)AVR5e
[0396] Lys399Glu and Asn487Asp were selected from the amino acid substitutions related to improved stability to heat and acid identified in Example 6, and were incorporated into AVR3 (SEQ ID NO: 32) to produce AVR5e. Specifically, a mutation introducing Lys399Glu was performed on the polynucleotide (SEQ ID NO: 39) encoding AVR4d (SEQ ID NO: 38) produced in (b), thereby producing AVR5e.
[0397] (d-1) Using pET-AVR4d obtained in (b-5) as a template and oligonucleotides consisting of the sequences described in sequence number 44 (5'-TTTT[GGTCTC]ACTTGCGTGGCTCCGGTTCCACGGTAACG-3') and sequence number 45 (5'-TTTT[GGTCTC]ACAAGAACCGTCCTCCGATCGCCATTG-3') as PCR primers (the square brackets in sequence numbers 44 and 45 represent the recognition sequence of the restriction endonuclease BsaI), the same method as (c-1) to (c-5) was used to obtain a plasmid pET-AVR5e containing a polynucleotide encoding AVR5e, wherein the AVR5e has undergone 5 amino acid substitutions relative to the wild-type AAV binding protein.
[0398] (d-2) The nucleotide sequence of pET-AVR5e was analyzed by the same method as in Example 1 (5).
[0399] Sequentially, the amino acid sequence of AVR5e to which a signal sequence and a polyhistidine tag are added is shown in sequence number 46; the sequence of the polynucleotide encoding the AVR5e is shown in sequence number 47. It should be noted that in sequence number 46, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR5e (corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In addition, in sequence number 46, cysteine of Tyr342Cys is present at position 55, serine of Gly390Ser is present at position 103, glutamic acid of Lys399Glu is present at position 112, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0400] Example 8 Evaluation of Acid Stability of Mutant AAV Binding Proteins (Part 2)
[0401] (1) After the transformants expressing the mutant AAV binding protein AVR3 obtained in Example 6 and the mutant AAV binding proteins (AVR4a, AVR4d, AVR5b and AVR5e) prepared in Example 7 are cultured using the methods described in (4) and (5) of Example 3, the culture fluid is centrifuged to obtain the culture supernatant containing each expressed mutant AAV binding protein.
[0402] (2) The binding activity of the mutant AAV binding protein to VLP2 in the culture supernatant obtained in (1) was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the culture supernatant obtained in (1) was diluted with pure water so that the measurement value became the same.
[0403] (3) Divide the diluted mutant AAV binding protein solutions into 4 portions and mix them with an equal amount of 0.1 M glycine hydrochloride buffer (pH 3.0). For 3 of the 4 samples, heat treatment was performed at 51.5°C, 60.1°C, and 66.1°C for 15 minutes, and the remaining portion was allowed to stand at room temperature (25°C) for 15 minutes. Thereafter, the sample was mixed with 0.5 M MES buffer (pH 6.0) at a ratio of 3:2 to adjust the pH to around 6, and the binding activity with VLP2 was measured using the ELISA method described in (6) of Example 2.
[0404] (4) The residual activity was calculated by dividing the absorbance at 450 nm when the heat and acid treatment described in (3) was performed by the absorbance at 450 nm when the sample was left standing at room temperature.
[0405] The results are shown in Table 11. The mutant AAV binding proteins (AVR3, AVR4a, AVR4d, AVR5b, AVR5e) prepared in Example 7 were treated at any temperature, and the residual activity was higher than that of AVR3 (No. 75 in Table 7). It can be seen that the five mutant AAV binding proteins have significantly improved stability to heat treatment under acidic conditions, i.e., to acid and heat, compared with the wild-type AAV binding protein.
[0406] [Table 11]
[0407]
[0408] Example 9 Preparation of mutant AAV binding protein with improved C-terminus
[0409] (1) Using pET-AVR5e prepared in Example 7(d) as a template and oligonucleotides consisting of the sequences described in SEQ ID NOs. 3 and 48 (5'-AT[CTCGAG]TCATCCGCAGGTATCGTTGCGGCAATGATGATGATGATGATGGTCTAC-3') as PCR primers (the square brackets in SEQ ID NO. 48 represent the recognition sequence of the restriction endonuclease XhoI), a reaction solution with the composition shown in Table 12 was prepared. The reaction solution was heat-treated at 94°C for 2 minutes, and then PCR was performed by repeating 25 cycles of a reaction consisting of a first step at 98°C for 10 seconds, a second step at 52°C for 30 seconds, and a third step at 68°C for 1.5 minutes as one cycle.
[0410] [Table 12]
[0411]
[0412] (2) The PCR product obtained in (1) was subjected to agarose gel electrophoresis, purified from the gel using QIAquick Gel Extraction kit (manufactured by QIAGEN), digested with restriction endonucleases NcoI and XhoI, and then ligated with expression vector pET26b (manufactured by MERCK MILLIPORE) that had been previously digested with restriction endonucleases NcoI and XhoI. The ligated product was used to transform Escherichia coli BL21 strain (DE3).
[0413] (3) The obtained transformant was cultured in LB medium containing 50 μg / mL kanamycin, and then the plasmid pET-AVR5eHC encoding a protein having an immobilization tag at the C-terminus of AVR5e (named AVR5eHC) was obtained using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0414] (4) The nucleotide sequence of the obtained pET-AVR5eHC was analyzed by the same method as in Example 1 (5).
[0415] The nucleotide sequence of AVR5eHC is shown in sequence number 49, and the amino acid sequence is shown in sequence number 50. It should be noted that in sequence number 50, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR5e; the histidine (His) at positions 214 to 219 are the histidine tag; and the cysteine (Cys) at position 220 to the glycine (Gly) at position 226 are the cysteine tag sequence as a tag for fixation.
[0416] Example 10 Large-scale preparation of mutant AAV binding proteins with improved C-terminus
[0417] (1) The transformant expressing AVR5eHC obtained by transforming Escherichia coli BL21 (DE3) strain with pET-AVR5eHC prepared in (3) of Example 9 was inoculated into a 200-mL baffled flask to which 40 mL of liquid culture medium (16 g / L Phytone peptone, 10 g / L yeast extract, 5 g / L sodium chloride) containing 50 μg / mL kanamycin was added, and cultured aerobically at 37°C for 10 hours to perform pre-culture.
[0418] (2) After 10 mL of the pre-culture solution of (1) was inoculated into a 3 L fermenter (manufactured by Biott) containing 0.9 L of a liquid medium containing 20 g / L of glucose, 40 g / L of yeast extract, 6 g / L of trisodium phosphate dodecahydrate, 18 g / L of disodium hydrogen phosphate dodecahydrate, 2 g / L of ammonium chloride, 2 g / L of magnesium sulfate, 2 g / L of iron sulfate, 10 g / L of manganese chloride, and 50 mg / L of kanamycin sulfate, the main culture was started under the conditions of a set temperature of 30°C, a pH of 6.9 to 7.1, and an aeration rate of 3 VVM. The pH was controlled by using 50% (v / v) phosphoric acid as an acid and 14% (w / v) ammonia water as an alkali, respectively, and the dissolved oxygen was controlled by changing the stirring speed within the range of a lower limit of 500 rpm / an upper limit of 1000 rpm. After the start of the culture, at a time point when the glucose concentration could not be measured, a fed-batch medium (425 g / L of glucose, 140 g / L of yeast extract, and 12 g / L of magnesium sulfate heptahydrate) was added while controlling the dissolved oxygen.
[0419] (3) When the absorbance at 600 nm reaches about 100, the set temperature is controlled to be below 25°C. After confirming that the set temperature has been reached, 1.1 mL of 0.5 mM IPTG is added and the culture is continued at 25°C. The culture is stopped about 42 hours after the start of the culture, and the culture solution is centrifuged at 4°C and 8000 rpm for 20 minutes to recover the bacterial cells.
[0420] (4) The bacterial cells recovered in (3) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride and 20 mM imidazole at a concentration of 5 mL / 1 g (bacterial cells), and then the bacterial cells were disrupted using an ultrasonic generator (INSONETA 201M [manufactured by Kubota Corporation]) at 8°C for about 10 minutes at a power of about 150 W. The disrupted bacterial cell solution was centrifuged twice at 4°C for 20 minutes at 8,000 rpm to recover the supernatant.
[0421] (5) The supernatant obtained in (4) was injected into an XK26 / 20 column (manufactured by Cytiva) filled with 50 mL of NiSepharose 6 Fast Flow (manufactured by Cytiva) which had been equilibrated in advance with a Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution A"). After washing with the equilibration solution A, elution was performed with a 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0422] (6) The eluate obtained in (5) was dialyzed with a 20 mM Tris buffer (pH 7.4) containing 4 mM imidazole and 150 mM sodium chloride, and then injected into a 50 mL XK26 / 20 column (manufactured by Cytiva) filled with TALON Metal Affinity Resin (manufactured by Takara Bio Inc.) equilibrated with the same buffer. After washing with the buffer used for equilibration, elution was performed with a 20 mM Tris hydrochloric acid buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0423] (7) The eluate obtained in (6) was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride to prepare about 200 mg of AVR5eHC protein.
[0424] Example 11 Preparation of viral vector (AAV2-EGFP)
[0425] (1) The following nucleotide sequences were designed: a nucleotide sequence (SEQ ID NO: 52) having a restriction endonuclease EcoRI recognition sequence (GAATTC) added to the 5' end of a polynucleotide encoding EGFP (Enhanced green fluorescent protein) consisting of the amino acid sequence set forth in SEQ ID NO: 51, and a stop codon (TAG) and a BamHI recognition sequence (GGATTC) added to the 3' end.
[0426] (2) A polynucleotide consisting of the sequence described in SEQ ID NO: 52 was fully synthesized and cloned into a plasmid (commissioned to FASMAC and named pUC-EGFP). Escherichia coli JM109 strain was transformed with pUC-EGFP, and the obtained transformant was cultured. pUC-EGFP was extracted from the culture solution using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0427] (3) The pUC-EGFP obtained in (2) was digested with restriction endonucleases EcoRI and BamHI, and then ligated with the expression vector pAAV-CMV (manufactured by Takara Bio Inc.) previously digested with restriction endonucleases EcoRI and BamHI, and the ligated product was used to transform Escherichia coli JM109 strain. The obtained transformant was cultured in LB medium containing 100 μg / mL carbenicillin, and the vector pAAV-EGFP expressing EGFP was extracted using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0428] (4) The transformant obtained in (3) was cultured in a 5 L baffled flask with 1 L of 2YT medium containing 100 μg / mL of carbenicillin at 37°C with shaking overnight. After the culture was completed, the cells were recovered by centrifugation. Plasmid Mega Kit (manufactured by QIAGEN) was used to prepare pAAV-EGFP in large quantities from the recovered cells.
[0429] (5) Preparation of AAV2-EGFP
[0430] (5-1) Escherichia coli JM109 strain was transformed using pRC2-mi342 Vector (manufactured by Takara Bio Inc.) and pHelper Vector (manufactured by Takara Bio Inc.) Using the obtained transformant, the same operation as in (4) was carried out to prepare pRC2-mi342 and pHelper in large quantities.
[0431] (5-2) HEK293T cells were cultured in 10 T-225 flasks (manufactured by Thermo Fisher Scientific) containing 45 mL of D-MEM medium (manufactured by FUJIFILM Wako Pure Chemical Corporation) containing 10% (v / v) bovine serum. Gene introduction was performed by adding pAAV-EGFP prepared in (4), pRC2-mi342 prepared in (5-1), pHelper, and a complex of polyethyleneimine (manufactured by Polysciences), and static culture was performed for 3 days under the conditions of 5% (v / v) carbon dioxide and 37°C. After the culture, the detached cells were recovered by centrifugation, and the cells obtained from each of the 5 T-225 flasks were cryopreserved at -80°C.
[0432] (5-3) The frozen cells obtained in (5-2) were thawed and suspended in 10 mL of 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride, 4 mM magnesium chloride and 0.01% (w / v) Tween 20 (trade name). 1 / 20 amount of Benzonase (Merck Millipore) was added, and after standing at 37°C for 1 hour, the supernatant was obtained by centrifugation at 13,000 × g and 4°C for 10 minutes. Ammonium sulfate was added to the obtained supernatant in a manner to make it 15% saturated, and centrifuged again under the same conditions. The obtained supernatant was supplied to a filter with a pore size of 0.45 μm to remove suspended matter.
[0433] (5-4) The supernatant from which the suspended matter has been removed is injected into a 5 mL AVB Sepharose column (manufactured by Cytiva) that has been pre-equilibrated with a 20 mM Tris-HCl buffer (pH 8.0) containing 0.5 M sodium chloride (hereinafter also referred to as "equilibration solution B"). After washing with equilibration solution B, elution is performed with a 0.1 M acetate buffer (pH 2.5) containing 0.5 M sodium chloride. To the obtained eluate, 1 / 4 amount of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride is added for neutralization to obtain an AAV2-EGFP solution serving as an AAV vector. The AAV2-EGFP concentration in the solution is quantified by qPCR using an AAVproTitration Kit (manufactured by Takara Bio Inc.).
[0434] Example 12 Preparation of AAV-binding protein immobilized gel (Part 1)
[0435] (1) The surface hydroxyl groups of a hydrophilic vinyl polymer for a separating agent (TOYOPEARL manufactured by TOSOH CORPORATION) were chemically modified to prepare a gel into which maleimide groups were introduced. 28 mg of the AVR5eHC protein prepared in Example 10 and 0.1 mM TCEP (Tris (2-carboxyethyl) phosphine) as a reducing agent were added to 3.5 g of the prepared gel, and the mixture was allowed to react under shaking conditions of pH 7.4 and 4° C. for 15 hours. Thus, a gel into which AVR5e was immobilized (named AVR5e immobilized gel) was prepared.
[0436] (2) 2 mL of the AVR5e immobilized gel prepared in (1) was filled into a Tricorn 10 / 50 column (manufactured by Cytiva) to prepare a column (named AVR5e column). The AVR5e column was connected to AKTAprime plus (manufactured by Cytiva), and after equilibration with 50 mM phosphate buffer (pH 7.4) containing 150 mM sodium chloride and 0.05% (w / v) Tween 20 (trade name) (hereinafter also referred to as "equilibration solution C"), 10 mL of the cell extract containing AAV2-EGFP obtained in (5-3) of Example 11 was injected at a flow rate of 1 mL / min.
[0437] (3) After washing with equilibration solution C, AAV2-EGFP was eluted from the AVR5e column with 0.1 M acetate buffer (pH 2.5) containing 0.5 M sodium chloride. 1 mL of the eluate was taken at a time and recovered in the form of fractions. 250 μL of 1 M Tris hydrochloric acid buffer (pH 8.5) containing 20 mM magnesium chloride was added to the recovered fractions for neutralization.
[0438] (4) In order to compare the purity of the eluate obtained in (3) with the cell extract obtained in (5-3) of Example 10 as a sample before purification, SDS-PAGE was performed and silver staining was performed using Pierce Silver Stain Kit (manufactured by ThermoFisher Scientific).
[0439] The chromatograms obtained using the AVR5e column in (3) are shown in Figure 2 The results of SDS-PAGE of (4) are shown in Figure 3 The peak of AAV2-EGFP appears around 20 minutes of elution time ( Figure 2 ). The fractions corresponding to the peak (Fr6 to Fr9) were subjected to SDS-PAGE, and the results showed that only the bands corresponding to VP1, VP2, and VP3 constituting AAV were confirmed ( Figure 3 On the other hand, in addition to the above-mentioned bands, numerous bands derived from inclusions can be confirmed in the cell extract injected into the AVR5e column ( Figure 3 ). From the above results, it can be seen that AAV can be purified to a high purity by using an AAV adsorbent comprising a gel and the AAV-binding protein of the present invention immobilized on the gel.
[0440] Example 13 Preparation and screening of mutant library of AAV binding protein (Part 3)
[0441] AVR5e (Tyr342Cys, Gly390Ser, Lys399Glu, Ser476Arg and Asn487Asp substitution; sequence number 46) was selected from the mutant AAV binding proteins evaluated in Example 7, and random mutation introduction was performed on the polynucleotide portion encoding the protein by error-prone PCR.
[0442] (1) After preparing a reaction solution of the composition shown in Table 6 using plasmid pET-AVR5e into which a polynucleotide (SEQ ID NO: 47) encoding AVR5e (SEQ ID NO: 46) was inserted as a template, error-prone PCR was performed under the same temperature conditions as in (1) of Example 3. By the error-prone PCR, mutations were introduced into the polynucleotide encoding AVR5e at an average mutation rate of 1.7 amino acid mutations per molecule.
[0443] (2) After purifying the PCR product obtained in (1), a random mutant library is prepared by the methods described in (2) and (3) of Example 6, and the library (transformants) is cultured by the methods described in (4) and (5) of Example 3.
[0444] (3) The culture solution obtained in (2) was centrifuged and the obtained culture supernatant was diluted 32 times with ultrapure water. 60 μL of the diluted culture solution was mixed with 60 μL of 0.1 M glycine hydrochloride buffer (pH 3.0), and subjected to heat and acid treatment at 61.0°C for 15 minutes.
[0445] (4) The binding activity of the AAV binding protein to VLP2 when subjected to the treatment of (3) and when not subjected to the treatment of (3) were measured using the ELISA method described in (6) of Example 2. The residual activity was calculated by dividing the binding activity of the AAV binding protein to VLP2 when subjected to heat treatment by the binding activity of the AAV binding protein to VLP2 when not subjected to heat treatment.
[0446] (5) The random mutant library of about 1,800 strains was evaluated using the method of (4), and transformants expressing AAV binding proteins with improved residual activity compared to the parent molecule AVR5e were selected. The selected transformants were cultured and expression vectors were prepared using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0447] (6) The nucleotide sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed by the method described in (5) of Example 1 to determine the amino acid mutation site.
[0448] The amino acid substitution sites of the AAV binding proteins expressed by the transformants selected in (5) relative to AVR5e (Tyr342Cys, Gly390Ser, Lys399Glu, Ser476Arg and Asn487Asp substitutions) and the residual activities (%) after heat and acid treatment are summarized and shown in Table 13.
[0449] In the amino acid sequence described in SEQ ID NO: 1, Val317Asp, Gln318Pro, Thr320Ala, Asn324Asp, Val326Ala, Val326Glu, Leu328Pro, Asn329His, Val332Ala, Lys362Glu, Lys362Asn, Lys371Glu, Lys It can be said that the AAV binding protein with at least one of the amino acid substitutions of 371Asn, Leu376Pro, Glu378Gly, Glu378Val, Phe379Ser, Phe379Tyr, Val381Asp, Gly392Cys, Thr397Ser, Glu401Val, Arg406His, Asn492Asp and Val499Glu has improved stability to heat and acid compared to the wild-type AAV binding protein.
[0450] [Table 13]
[0451]
[0452] Example 14 Integration of stabilizing amino acid substitutions (Part 2)
[0453] The amino acid substitutions related to the improved heat and acid stability of the AAV binding protein determined in Example 13 were integrated into AVR5e (sequence number 46) to seek further stability improvement. Specifically, No. 93 (amino acid substitutions of Asn324Asp and Lys362Glu were integrated into AVR5e) (named AVR7a) and No. 91 (amino acid substitutions of Val317Asp and Lys371Asn were integrated into AVR5e) (named AVR7b) in the (mutant) AAV binding proteins with amino acid substitutions shown in Table 13 were selected, and the amino acid substitutions shown in (a) or (b) below were integrated into the protein. It should be noted that, respectively, the substitution of Asn324Asp in the amino acid sequence of AVR7a (sequence number 53) is located at position 37 in sequence number 53, and the substitution of Lys362Glu is located at position 75 in sequence number 53. Furthermore, in the amino acid sequence of AVR7b (SEQ ID NO: 55), the substitution of Val317Asp is located at position 30 in SEQ ID NO: 55, and the substitution of Lys371Asn is located at position 84 in SEQ ID NO: 55.
[0454] (a) Val317Asp was introduced into AVR7a (named AVR8a)
[0455] (b) Lys362Glu was introduced into AVR7b (named AVR8g)
[0456] Hereinafter, methods for producing each AAV-binding protein will be described in detail.
[0457] (a) AVR8a
[0458] From the amino acid substitutions related to improved stability to heat and acid identified in Example 13, Val317Asp was selected and incorporated into AVR7a (SEQ ID NO: 53) to produce AVR8a. Specifically, AVR8a was produced by introducing a mutation that produces Val317Asp into a polynucleotide (SEQ ID NO: 54) encoding AVR7a (SEQ ID NO: 53).
[0459] (a-1) Plasmid pET-AVR7a into which a polynucleotide encoding AVR7a (SEQ ID NO: 54) was inserted was used as a template, and oligonucleotides consisting of the sequences described in SEQ ID NO: 57 (5'-TTTT[GGTCTC]AGCAGGCGAGTCGGATCAGATTACCC-3') and SEQ ID NO: 58 (5'-TTTT[GGTCTC]ACTGCAGAGCCCATGGCCATCGCCGG-3') (the square brackets in SEQ ID NO: 57 and 58 indicate a restriction endonuclease BsaI recognition sequence) were used as PCR primers to prepare a reaction solution of the composition shown in Table 12. The reaction solution was heat-treated at 98°C for 5 minutes, and PCR was performed by performing 30 cycles of a reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treated at 72°C for 5 minutes.
[0460] (a-2) The amplified PCR product was subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction Kit (manufactured by QIAGEN). The purified PCR product was named 8ap.
[0461] (a-3) 8ap obtained in (a-2) was treated with restriction endonuclease DpnI (manufactured by NEB) at 37°C for 1.5 hours. Thereafter, the gene was subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction kit (manufactured by QIAGEN).
[0462] (a-4) The DpnI-treated product obtained in (a-3) was digested with restriction endonuclease BsaI (manufactured by NEB) in a reaction solution having the composition shown in Table 10 and ligated with T4 DNA ligase (manufactured by NEB).
[0463] (a-5) The ligation product of (a-4) was used to transform Escherichia coli BL21 strain (DE3). The obtained transformant was cultured in LB medium supplemented with 50 μg / mL of kanamycin. The plasmid was extracted from the recovered bacteria (transformant) to obtain a plasmid pET-AVR8a containing a polynucleotide encoding AVR8a, wherein the AVR8a was subjected to 8 amino acid substitutions relative to the wild-type AAV binding protein.
[0464] (a-6) The nucleotide sequence of pET-AVR8a was analyzed by the same method as in Example 1 (5).
[0465] Sequentially, the amino acid sequence of AVR8a to which a signal sequence and a polyhistidine tag are added is shown in sequence number 59; the sequence of the polynucleotide encoding the AVR8a is shown in sequence number 60. It should be noted that in sequence number 59, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR8a (domain 1 and domain 2, corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In addition, in sequence number 59, aspartic acid of Val317Asp is present at position 30, aspartic acid of Asn324Asp is present at position 37, cysteine of Tyr342Cys is present at position 55, glutamic acid of Lys362Glu is present at position 75, serine of Gly390Ser is present at position 103, glutamic acid of Lys399Glu is present at position 112, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0466] (b)AVR8g
[0467] Lys362Glu was selected from the amino acid substitutions related to improved stability to heat and acid identified in Example 13, and was incorporated into AVR7b (SEQ ID NO: 55) to produce AVR8g. Specifically, AVR8g was produced by introducing a mutation that produces Lys362Glu into a polynucleotide (SEQ ID NO: 56) encoding AVR7b (SEQ ID NO: 55).
[0468] (b-1) Using the plasmid pET-AVR7b into which the polynucleotide encoding AVR7b (sequence number 56) was inserted as a template and oligonucleotides consisting of the sequences described in sequence number 61 (5'-TTTT[GGTCTC]ACGAGATGGAAGGAGAACATTCGCAG-3') and sequence number 62 (5'-TTTT[GGTCTC]ACTCGCCGCTGTAGTCGCGAGG-3') as PCR primers (the square brackets in sequence numbers 61 and 62 represent the recognition sequence of the restriction endonuclease BsaI), the same method as (a-1) to (a-5) was used to obtain a plasmid pET-AVR8g containing a polynucleotide encoding AVR8g in which 8 amino acids were substituted relative to the wild-type AAV binding protein.
[0469] (b-2) The nucleotide sequence of pET-AVR8g was analyzed by the same method as in Example 1 (5).
[0470] Sequentially, the amino acid sequence of AVR8g to which a signal sequence and a polyhistidine tag are added is shown in sequence number 63; the sequence of the polynucleotide encoding the AVR8g is shown in sequence number 64. It should be noted that in sequence number 63, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR8g (domain 1 and domain 2, corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In addition, in sequence number 63, aspartic acid of Val317Asp is present at position 30, cysteine of Tyr342Cys is present at position 55, glutamic acid of Lys362Glu is present at position 75, aspartic acid of Lys371Asn is present at position 84, serine of Gly390Ser is present at position 103, glutamic acid of Lys399Glu is present at position 112, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0471] Example 15 Evaluation of Acid Stability of Mutant AAV Binding Proteins (Part 3)
[0472] (1) After the transformants expressing the mutant AAV binding protein AVR7a obtained in Example 13 and the mutant AAV binding proteins (AVR8a and AVR8g) prepared in Example 14 are cultured using the methods described in (4) and (5) of Example 3, the culture fluid is centrifuged to obtain the culture supernatant containing each expressed mutant AAV binding protein.
[0473] (2) The binding activity of the mutant AAV binding protein to VLP2 in the culture supernatant obtained in (1) was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the culture supernatant obtained in (1) was diluted with pure water so that the measurement value became the same.
[0474] (3) The diluted mutant AAV binding protein solutions were divided into three parts and mixed with an equal amount of 0.1 M glycine hydrochloride buffer (pH 3.0). Two of the three samples were heated at 80.8°C and 89.8°C for 15 minutes, and the remaining sample was left standing at room temperature (25°C) for 15 minutes. Thereafter, the sample was mixed with 0.5 M MES buffer (pH 6.0) at a ratio of 3:2 to adjust the pH to around 6, and the binding activity with VLP2 was measured using the ELISA method described in (6) of Example 2.
[0475] (4) The residual activity was calculated by dividing the absorbance at 450 nm when the heat and acid treatment described in (3) was performed by the absorbance at 450 nm when the sample was left standing at room temperature.
[0476] The results are shown in Table 14. When the mutant AAV binding proteins (AVR8a, AVR8g) prepared in Example 14 were treated at 80.8°C, the residual activity was higher than that of AVR7a (No. 93 in Table 14). It can be seen that the two mutant AAV binding proteins have significantly improved stability to heat treatment under acidic conditions, i.e., to acid and heat, compared with the wild-type AAV binding protein.
[0477] [Table 14]
[0478]
[0479] Example 16 Preparation and Screening of Mutant Library of AAV Binding Protein (Part 4)
[0480] AVR8g (Val317Asp, Tyr342Cys, Lys362Glu, Lys371Asn, Gly390Ser, Lys399Glu, Ser476Arg and Asn487Asp substitution; sequence number 63) was selected from the mutant AAV binding proteins evaluated in Example 15, and random mutation introduction was performed on the polynucleotide portion encoding the protein by error-prone PCR.
[0481] (1) Using plasmid pET-AVR8g into which a polynucleotide (SEQ ID NO: 64) encoding AVR8g (SEQ ID NO: 63) was inserted as a template, a reaction solution of the composition shown in Table 6 was prepared, and then error-prone PCR was performed under the same temperature conditions as in (1) of Example 3. By the error-prone PCR, mutations were introduced into the polynucleotide encoding AVR8g at an average mutation rate of 2.3 amino acid mutations per molecule.
[0482] (2) After purifying the PCR product obtained in (1), a random mutant library is prepared by the methods described in (2) and (3) of Example 6, and the library (transformants) is cultured by the methods described in (4) and (5) of Example 3.
[0483] (3) The culture solution obtained in (2) was centrifuged and the obtained culture supernatant was diluted 16-fold with ultrapure water. 60 μL of the diluted culture solution was mixed with 60 μL of 0.1 M glycine sodium hydroxide buffer (pH 10.0), and subjected to heat and alkali treatment at 41.2°C for 15 minutes.
[0484] (4) The binding activity of the AAV binding protein to VLP2 when subjected to the treatment of (3) and when not subjected to the treatment of (3) were measured using the ELISA method described in (6) of Example 2. The residual activity was calculated by dividing the binding activity of the AAV binding protein to VLP2 when subjected to heat treatment by the binding activity of the AAV binding protein to VLP2 when not subjected to heat treatment.
[0485] (5) The random mutant library of about 1,800 strains was evaluated using the method of (4), and transformants expressing AAV binding proteins with improved residual activity compared to AVR8g as the parent molecule were selected. The selected transformants were cultured and expression vectors were prepared using QIAprep Spin Miniprep kit (manufactured by QIAGEN).
[0486] (6) The nucleotide sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed by the method described in (5) of Example 1 to determine the amino acid mutation site.
[0487] (7) The amino acid substitution sites of the AAV binding protein expressed by the transformant selected in (6) relative to AVR8g (Val317Asp, Tyr342Cys, Lys362Glu, Lys371Asn, Gly390Ser, Lys399Glu, Ser476Arg and Asn487Asp substitutions) and the residual activity (%) after heat and alkali treatment are summarized and shown in Table 15.
[0488] In the amino acid sequence described in SEQ ID NO: 1, the amino acid residues from the 312th serine (Ser) to the 500th aspartic acid (Asp) are Ser312Pro, Ala313Ser, Lys323Arg, Asn324Ser, Gln327His, Gln327Leu, Asn329Ile, Glu335Gly, Glu335Val, Glu340Val, Thr341Pro, Thr343Ser, Tyr 344Phe、Trp346Cys、Arg353Cys、Tyr355Cys、Ser356Cys、Gly357Cys、Met359Leu、Glu360Lys、Glu360Val、Gly 361Cys, Lys(Glu)362Gly, Ser364Leu, Ile366Thr, Leu369Gln, Lys(Asn)371Asp, Leu372Pro, Leu372Gln, Thr3 73Ala, Pro374Leu, Leu376Pro, Glu378Gly, Glu378Val, Phe379Cys, Phe379Ser, Lys380Glu, Val381Ala, Ile3 82Val, Val383Ala, Glu384Val, Gln386Arg, His389Arg, Tyr393Cys, Val394Asp, Val394Ile, Asn395Ser, Val3 It can be said that the AAV binding protein with at least one of the amino acid substitutions of 96Ala, Arg403His, Gln415Arg, Thr426Ala, Gln432Leu, Gln432Arg, Gln441Arg, His443Leu, Lys448Glu, Ile456Val, Asp483Asn, Ser488Leu, and Val499Ile has improved stability to heat and alkali compared to the wild-type AAV binding protein.
[0489] [Table 15]
[0490]
[0491] Example 17 Monomerization of mutant AAV binding protein (Part 1)
[0492] No. 143 (amino acid substitutions of Val381Ala and Ile382Val were integrated into AVR8g) (named AVR10) was selected from the mutant AAV binding proteins with improved stability to heat and alkali as identified in Example 16, and the amino acid substitution of Tyr (Cys) 342Ser (named AVR10s) was introduced to monomerize the protein. Specifically, AVR10s was prepared by introducing a mutation that produces Tyr (Cys) 342Ser into a polynucleotide (sequence number 66) encoding AVR10 (sequence number 65). It should be noted that, respectively, the substitution of Val381Ala in the amino acid sequence of AVR10 (sequence number 65) is located at the 94th position in sequence number 65, and the substitution of Ile382Val is located at the 95th position in sequence number 65.
[0493] (1) Using pET26b-AVR10 into which a polynucleotide encoding AVR10 (sequence number 66) was inserted as a template and oligonucleotides consisting of the sequences described in sequence number 67 (5'-TTTT[GGTCTC]AGAAACCTCTACGTATGACTG-3') and sequence number 68 (5'-TTTT[GGTCTC]ATTTCCCCTTTCGGTGG-3') as PCR primers (the square brackets in sequence numbers 67 and 68 represent the recognition sequence of the restriction endonuclease BsaI), a plasmid pET-AVR10s containing a polynucleotide encoding AVR10s in which 10 amino acid substitutions were made relative to the wild-type AAV binding protein was obtained in the same manner as (a-1) to (a-5) of Example 14.
[0494] (2) The nucleotide sequence of pET-AVR10s was analyzed by the same method as in Example 1 (5).
[0495] Sequentially, the amino acid sequence of AVR10s to which a signal sequence and a polyhistidine tag are added is shown in sequence number 69; the sequence of the polynucleotide encoding the AVR10s is shown in sequence number 70. It should be noted that in sequence number 69, the methionine (Met) at position 1 to the alanine (Ala) at position 22 are the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 are the AAV binding protein AVR10s (corresponding to the region from position 312 to position 500 of sequence number 1), and the histidine (His) at positions 214 to 219 are the tag sequence. In addition, in sequence number 69, aspartic acid of Val317Asp is present at position 30, serine of Tyr(Cys)342Ser is present at position 55, glutamic acid of Lys362Glu is present at position 75, asparagine of Lys371Asn is present at position 84, alanine of Val381Ala is present at position 94, valine of Ile382Val is present at position 95, serine of Gly390Ser is present at position 103, glutamic acid of Lys399Glu is present at position 112, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0496] Example 18 Monomerization of mutant AAV binding protein (Part 2)
[0497] In order to monomerize the mutant AAV binding protein AAV5eHC prepared in Example 9, the amino acid substitution of Tyr(Cys)342Met was introduced, and PKD3 (amino acid residues from tyrosine at position 501 to lysine at position 597 of sequence number 1) was further added to prepare a mutant AAV binding protein (named AVR5eMHCD3). Specifically, a mutation generating Tyr(Cys)342Met was introduced into a polynucleotide (sequence number 49) encoding AVR5eHC (sequence number 50), and then PKD3 was added to prepare AVR5eMHCD3.
[0498] (1) Using pET26b-AVR5eHC as a template and oligonucleotides consisting of sequences recorded in sequence numbers 71 (5'-TTTT[GGTCTC]AGAAACCATGACGTATGACTG-3') and 68 (the square brackets in sequence numbers 71 and 68 represent the recognition sequence of the restriction endonuclease BsaI) as PCR primers, the same method as (a-1) to (a-5) of Example 14 was used to obtain a plasmid pET-AVR5eMHC containing a polynucleotide encoding a mutant AAV binding protein into which the amino acid substitution of Tyr(Cys)342Met was introduced relative to AVR5eHC.
[0499] (2) PCR was performed in the same manner as in Example 14 (a-1), except that pUC-AAVR was used as a template and oligonucleotides consisting of the sequences described in sequence number 72 (5'-TTTT[GGTCTC]AGATGTTTGTTATTTTCGGGCTGAACAATC-3') and sequence number 73 (5'-TTTT[GGTCTC]AAGACTATCCGCCGGTAGCGAACGC-3') (the square brackets in sequence numbers 72 and 73 represent the recognition sequence of the restriction endonuclease BsaI) as PCR primers.
[0500] (3) Using pET26b-AVR5eMHC prepared in (1) as a template and oligonucleotides consisting of the sequences recorded in sequence number 74 (5'-TTTT[GGTCTC]AGTCTACCGCTTTGTTG-3') and sequence number 75 (5'-TTTT[GGTCTC]ACATCATCATCATCATCAT-3') as PCR primers (the square brackets in sequence numbers 74 and 75 represent the recognition sequence of the restriction endonuclease BsaI), PCR was carried out using the same method as (a-1) of Example 14.
[0501] (4) The PCR products amplified in (2) and (3) were subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction kit (manufactured by QIAGEN). The purified PCR product of (2) was named D3p, and the purified PCR product of (3) was named 5MVp.
[0502] (5) D3p and 5Mvp obtained in (4) were treated with restriction endonuclease DpnI (manufactured by NEB) at 37°C for 1.5 hours. Thereafter, the treated at 80°C for 20 minutes, and the obtained genes were subjected to agarose gel electrophoresis and purified from the gel using QIAquick Gel Extraction kit (manufactured by QIAGEN).
[0503] (6) The DpnI-treated product obtained in (5) was digested with restriction endonuclease BsaI (manufactured by NEB) in a reaction solution having the composition shown in Table 16 and ligated with T4 DNA ligase (manufactured by NEB).
[0504] [Table 16]
[0505] composition volume 20ng / μL PCR product (D3p) 5μL 20ng / μL PCR product (5MVp) 5μL 10× CutSmart Buffer (NEB) 1.5μL Bsa I (made by NEB) 1μL T4 DNA ligase buffer (manufactured by NEB) 1.5μL T4 DNA ligase (NEB) 1μL <![CDATA[H2O]]> Make up to 15 μL
[0506] (7) The ligation product of (6) was used to transform Escherichia coli BL21 strain (DE3). The obtained transformants were cultured in LB medium supplemented with 50 μg / mL of kanamycin. The plasmid was extracted from the recovered bacteria (transformants) to obtain a plasmid pET-AVR5eMHCD3 containing a polynucleotide encoding a mutant AAV binding protein to which AVR5eHD was monomerized and PKD3 was added.
[0507] (8) The nucleotide sequence of pET-AVR5eMHCD3 was analyzed by the same method as in Example 1 (5).
[0508] The amino acid sequence of AVR5eMHCD3 is shown in SEQ ID NO: 76, and the sequence of the polynucleotide is shown in SEQ ID NO: 77, respectively. It should be noted that in sequence number 76, the methionine (Met) at position 1 to the alanine (Ala) at position 22 is the PelB signal peptide; the serine (Ser) at position 25 to the aspartic acid (Asp) at position 213 is the AAV binding protein AVR5eMHC (corresponding to the region from position 312 to position 500 of sequence number 1), the tyrosine (Tyr) at position 214 to the lysine (Lys) at position 310 is the AAV extracellular region domain 3 (PKD3) (the region from position 501 to position 597 of sequence number 1), the histidine (His) at position 311 to position 316 is the tag sequence, and the cysteine (Cys) at position 317 to the glycine (Gly) at position 323 is a cysteine tag used as a fixation tag. In addition, in sequence number 76, methionine of Tyr(Cys)342Met is present at position 55, serine of Gly390Ser is present at position 103, glutamic acid of Lys399Glu is present at position 112, arginine of Ser476Arg is present at position 189, and aspartic acid of Asn487Asp is present at position 200.
[0509] Example 19 Preparation of Monomeric Mutant AAV Binding Protein (Part 1)
[0510] (1) A transformant capable of expressing AVR10s obtained by transforming the Escherichia coli strain BL21 (DE3) with pET-AVR10s prepared in Example 17, or a transformant capable of expressing AVR5eMHCD3 obtained by transforming the Escherichia coli strain BL21 (DE3) with pET-AVR5eMHCD3 prepared in Example 18, was inoculated into 3 mL of 2YT liquid culture medium containing 50 μg / mL kanamycin and cultured aerobically at 37°C overnight to perform pre-culture.
[0511] (2) 2 mL of the preculture solution of (1) was inoculated into 200 mL of 2YT liquid medium supplemented with 50 μg / mL kanamycin in a 1 L baffled flask, and cultured aerobically at 37°C.
[0512] (3) 2.0 hours after the start of the culture, the cells were cooled on ice, IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 0.1 mM, and then cultured overnight at 25°C with aerobic shaking.
[0513] (4) After the culture was completed, the culture solution was centrifuged at 4°C and 8000 rpm for 20 minutes to recover the bacterial cells.
[0514] (5) The bacterial cells recovered in (4) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole at a concentration of 5 mL / 1 g (bacterial cells), and then the bacterial cells were disrupted using an ultrasonic generator (INSONETA 201M [manufactured by Kubota Corporation]) at 8°C for about 10 minutes at a power of about 150 W. The disrupted bacterial cell solution was centrifuged twice at 4°C for 20 minutes at 8,000 rpm to recover the supernatant.
[0515] (6) The supernatant obtained in (5) was injected into an XK26 / 20 column (manufactured by Cytiva) filled with 50 mL of NiSepharose 6 Fast Flow (manufactured by Cytiva) that had been equilibrated in advance with a Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution D"). After washing with the equilibration solution D, elution was performed with a 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0516] (7) The eluate obtained in (6) was dialyzed against 20 mM Tris buffer (pH 7.4) containing 150 mM sodium chloride to prepare an amount of AVR10s protein or AVR5eMHCD3 protein required for thermal stability evaluation.
[0517] Example 20 Evaluation of thermal stability of mutant AAV binding proteins (Part 4)
[0518] (1) The binding activity of AVR10s prepared in Example 18 to VLP2 was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the AVR10s solution was diluted with pure water so that the measurement values would be the same.
[0519] (2) The diluted AVR10s solution was divided into four parts and mixed with an equal amount of 0.1M glycine hydrochloride buffer (pH 3.0). Three of the four samples were heated at 31.7°C, 41.2°C, and 50.0°C for 15 minutes, and the remaining one was left to stand at room temperature (25°C) for 15 minutes. After that, the sample was mixed with 0.5M MES buffer (pH 6.0) at a ratio of 3:2 to adjust the pH to around 6, and the binding activity with VLP2 was measured using the ELISA method described in (6) of Example 2.
[0520] (3) The residual activity was calculated by dividing the absorbance at 450 nm when the heat treatment described in (2) was performed by the absorbance at 450 nm when the sample was left standing at room temperature.
[0521] (4) As a comparison object, the thermal stability of the wild-type AAV binding protein (SEQ ID NO: 7) was evaluated using the same methods as (1) to (3).
[0522] The results are shown in Table 17. The mutant AAV binding protein AVR10s prepared in Example 17 had higher residual activity than the wild-type AAV binding protein when treated at any temperature. It can be seen that the heat treatment under acidic conditions, i.e., the stability to acid and heat, of AVR10s is significantly improved compared to the wild-type AAV binding protein.
[0523] [Table 17]
[0524]
[0525] Example 21 Evaluation of thermal stability of mutant AAV binding proteins (Part 5)
[0526] (1) The binding activity of AVR5eMHCD3 prepared in Example 18 to VLP2 was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm as the measurement result, the AVR5eMHCD3 solution was diluted with pure water so that the measurement values would be the same.
[0527] (2) The diluted AVR5eMHCD3 solution was divided into 4 portions and diluted 2-fold with pure water. Three of the 4 samples were heated at 51.7°C, 66.4°C, and 70.0°C for 15 minutes, and the remaining portion was allowed to stand at room temperature (25°C) for 15 minutes. Afterwards, the sample was mixed with 20 mM Tris buffer (pH 7.4) containing 150 mM sodium chloride in a ratio of 3:2, and the binding activity with VLP2 was measured by the ELISA method described in (6) of Example 2.
[0528] (3) The residual activity was calculated by dividing the absorbance at 450 nm when the heat treatment described in (2) was performed by the absorbance at 450 nm when the sample was left standing at room temperature.
[0529] (4) As a comparison object, the thermal stability of the wild-type AAV binding protein (SEQ ID NO: 7) was evaluated using the same methods as (1) to (3).
[0530] The results are shown in Table 18. The mutant AAV binding protein AVR5eMHCD3 prepared in Example 18 had higher residual activity than the wild-type AAV binding protein when treated at any temperature. This shows that AVR5eMHCD3 has significantly improved thermal stability compared to the wild-type AAV binding protein.
[0531] [Table 18]
[0532]
[0533] Example 22 Preparation of AAV-binding protein immobilized gel (Part 2)
[0534] (1) A wild-type AAV binding protein fixed gel and an AVR5eHC fixed gel were prepared by the same method as in Example 12. Specifically, 10 mg of the AVR5eHC or wild-type AAV binding protein prepared in Example 10 and 0.1 mM TCEP as a reducing agent were added to 1 mL of the gel into which the maleimide group had been introduced, and the mixture was allowed to react by shaking for 15 hours at pH 7.4 and 4°C.
[0535] (2) The filtrate after fixation in (1) was measured by an absorption photometer, and the amount of unfixed protein was calculated, thereby estimating the amount of each protein fixed to the gel. The AVR5eHC fixed gel had 9 mg / mL (gel) of AVR5eHC fixed, and the wild-type AAV binding protein fixed gel had 10 mg / mL (gel) of wild-type AAV binding protein fixed.
[0536] (3) 0.065 mL of each immobilized gel prepared in (1) was added to Cosmo Spin Filter G (manufactured by NACALAITESQUE, INC.) to prepare microcolumns (named AVR5eHC immobilized gel microcolumn and wild-type AAV binding protein immobilized gel microcolumn, respectively). Each microcolumn was equilibrated with 50 mM phosphate buffer (pH 7.4) containing 150 mM sodium chloride and 0.05% (w / v) Tween 20 (trade name) (hereinafter also referred to as "solution A"), and then 2.9 × 10 10 VG (vector genome number).
[0537] (4) Using a shaking culture apparatus M·BR-022UP (manufactured by Taitec), shake at 1600 rpm for 5 minutes, centrifuge at 1000 G for 2 minutes, and recover the filtrate. Again, add 200 μL of solution A to the microcolumn, shake for 1 minute, centrifuge, and combine with the previous filtrate to recover 400 μL (hereinafter also referred to as "flow through").
[0538] (5) The column was washed twice with 400 μL of solution A, and each filtrate was recovered (the filtrates recovered for the first and second times were also referred to as "Wash 1" and "Wash 2", respectively). Then, 200 μL of 50 mM phosphate buffer (pH 2.5) containing 150 mM sodium chloride and 0.05% (w / v) Tween 20 (trade name) (hereinafter referred to as "Solution B") was added to each microcolumn, and after shaking for 5 minutes, centrifugation was performed to recover the eluate. 200 μL of solution B was added to the microcolumn again, and after shaking for 1 minute, centrifugation was performed, and the solution was combined with the previous eluate to recover 400 μL (hereinafter referred to as "Elute 1").
[0539] (6) Furthermore, 400 μL of solution B was added, centrifuged, and the eluate (hereinafter also referred to as "Elute 2") was recovered. To Elution 1 and Elution 2, 100 μL of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride was added for neutralization.
[0540] (7) The number of AAV2-EGFP vector genomes contained in the penetration obtained in (3), the wash 1, wash 2 and elution 1 obtained in (5), and the elution 2 obtained in (6) was quantified by qPCR using AAVpro Titration Kit (manufactured by Takara Bio Inc.).
[0541] The results are shown in Figure 4 . For the wild-type AAV binding protein-immobilized gel microcolumn, most of the injected AAV was confirmed in the penetration fraction; in contrast, for the AVR5eHC-immobilized gel microcolumn, almost all of the injected AAV was adsorbed to the gel, and elution from the gel was confirmed in the elution 1 fraction. From the above results, it can be seen that the AAV adsorbent comprising a gel and the AAV binding protein of the present invention immobilized on the gel can efficiently purify AAV compared to the case of using wild-type AVR.
[0542] Example 23 Preparation of AAV-binding protein immobilized gel (Part 3)
[0543] (1) Using the same method as in Example 9, pET-AVR3 and pET-AVR8g were used as templates to obtain pET-AVR3HC and pET-AVR8gHC. Furthermore, AVR3HC (a protein having a fixation tag at the C-terminus of AVR3) and AVR8gHC (a protein having a fixation tag at the C-terminus of AVR8g) were prepared using the same method as in Example 10. Using the prepared proteins, AVR3HC fixed gel and AVR8gHC fixed gel were prepared using the same method as in Example 22. Alternatively, a wild-type AAV binding protein fixed gel was prepared using the method described in Example 22.
[0544] (2) The filtrate after fixation in step (1) was measured with an absorption photometer to calculate the amount of unfixed protein, thereby estimating the amount of each protein fixed to the gel. The amount of AVR3HC fixed to the gel was 3.8 mg / mL (gel) of AVR3HC, and the amount of AVR8gHC fixed to the gel was 5.7 mg / mL (gel).
[0545] (3) The wild-type AAV binding protein immobilized gel prepared in (1), 0.065 mL of AVR3HC immobilized gel, and 0.018 mL of AVR8gHC immobilized gel were filled in Cosmo Spin Filter G (manufactured by NACALAI TESQUE, INC.), respectively, to prepare microcolumns (named as wild-type AAV binding protein immobilized gel microcolumn, AVR3HC immobilized gel microcolumn, and AVR8gHC immobilized gel microcolumn, respectively). After equilibration with 150 mM sodium chloride and 50 mM acetate buffer (pH 6.0) (hereinafter also referred to as "Solution A"), the AAV2-EGFP purified product obtained in Example 11 was injected into the breakthrough fraction multiple times until sufficient leakage of AAV2-EGFP could be confirmed. The final amount of AAV2-EGFP injected into each column was as follows: Wild-type AAV binding protein immobilized gel microcolumn 2.9×10 10 VG, AVR3HC fixed gel micro column 3.9×10 10 VG, AVR8gHC fixed gel microcolumn 2.4×10 11 VG.
[0546] (4) In order to elute and recover AAV2-EGFP bound to the gel, the column was washed twice with 200 μL of solution A, and each filtrate was recovered (hereinafter referred to as "wash 1"). Then, 200 μL of a buffer solution (pH 3.0) containing 150 mM sodium chloride and 50 mM acetate (hereinafter referred to as "solution B") was added to each microcolumn, and after shaking for 5 minutes, the eluate was recovered by centrifugation. 200 μL of solution B was added to the microcolumn again, and after shaking for 1 minute, the eluate was centrifuged and combined with the previous eluate to recover 400 μL (hereinafter referred to as "elution 1").
[0547] (5) Furthermore, 400 μL of solution B was added, centrifuged, and the eluate was recovered (hereinafter also referred to as "elution 2"). 100 μL of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride was added to eluate 1 and eluate 2 for neutralization.
[0548] (6) The number of AAV2-EGFP vector genomes contained in the penetration, wash 1, elution 1, and elution 2 obtained in (3) to (5) was quantified by qPCR using AAVpro Titration Kit (manufactured by Takara Bio Inc.).
[0549] The results are shown in Figure 5 It can be seen that most of the bound AAV2-EGFP was eluted and recovered in the elution 1 fraction. The amount of AAV2-EGFP bound to each microcolumn was converted to 1 mL of fixed gel based on the amount of AAV2-EGFP recovered by elution. The amount of wild-type AAV binding protein fixed gel was 8.6×10 9 VG / mL (gel); AVR3HC fixed gel is 2.8×10 12 VG / mL (gel); AVR8gHC fixed gel is 1.2×10 13 VG / mL (gel).
Claims
1. An adeno-associated virus (AAV) binding protein, the sequence of which is an amino acid sequence from serine at position 312 to aspartic acid at position 500 in the amino acid sequence described in SEQ ID NO:
1. in, An amino acid substitution as shown in any one of the following (A) to (K) occurs in the amino acid sequence from position 312 to position 500; (A) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, and the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine; (A1) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the isoleucine at position 319 of SEQ ID NO: 1 is substituted with phenylalanine; (A2) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the isoleucine at position 319 of SEQ ID NO: 1 is substituted with asparagine; (A3) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the lysine at position 323 of SEQ ID NO: 1 is substituted with glutamic acid; (A4) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, and leucine at position 328 of sequence number 1 is substituted with glutamine; (A5) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the leucine at position 328 of SEQ ID NO: 1 is substituted with proline; (A6) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the tyrosine at position 331 of SEQ ID NO: 1 is substituted with histidine; (A7) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the valine at position 332 of SEQ ID NO: 1 is substituted with alanine; (A8) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the valine at position 332 of SEQ ID NO: 1 is substituted with glutamic acid; (A9) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the leucine at position 333 of SEQ ID NO: 1 is substituted with proline; (A10) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the proline at position 337 of SEQ ID NO: 1 is substituted with glutamine; (A11) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, and the tyrosine at position 342 of SEQ ID NO: 1 is substituted with arginine; (A12) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the threonine at position 350 of SEQ ID NO: 1 is substituted with serine; (A13) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the valine at position 383 of SEQ ID NO: 1 is substituted with alanine; (A14) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the histidine at position 389 of SEQ ID NO: 1 is substituted with aspartic acid; (A15) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the valine at position 394 of SEQ ID NO: 1 is substituted with alanine; (A16) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the valine at position 396 of SEQ ID NO: 1 is substituted with alanine; (A17) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the serine at position 476 of SEQ ID NO: 1 is substituted with glycine; (A18) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the asparagine at position 492 of SEQ ID NO: 1 is substituted with aspartic acid; (A19) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, the leucine at position 321 of SEQ ID NO: 1 is substituted with proline, and the isoleucine at position 409 of SEQ ID NO: 1 is substituted with valine; (A20) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, the leucine at position 328 of SEQ ID NO: 1 is substituted with proline, and the isoleucine at position 366 of SEQ ID NO: 1 is substituted with phenylalanine; (A21) glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, lysine at position 338 of SEQ ID NO: 1 is substituted with asparagine, and asparagine at position 487 of SEQ ID NO: 1 is substituted with aspartic acid; (A22) glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, glutamine at position 365 of SEQ ID NO: 1 is substituted with arginine, and glycine at position 392 of SEQ ID NO: 1 is substituted with cysteine; (A23) glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, phenylalanine at position 379 of SEQ ID NO: 1 is substituted with serine, and serine at position 476 of SEQ ID NO: 1 is substituted with glycine; (A24) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, the serine at position 476 of SEQ ID NO: 1 is substituted with arginine, and the threonine at position 490 of SEQ ID NO: 1 is substituted with serine; (A25) glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, isoleucine at position 319 of SEQ ID NO: 1 is substituted with serine, threonine at position 320 of SEQ ID NO: 1 is substituted with isoleucine, and lysine at position 399 of SEQ ID NO: 1 is substituted with glutamic acid; (A26) glycine at position 390 of SEQ ID NO: 1 is substituted with serine, tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, proline at position 336 of SEQ ID NO: 1 is substituted with glutamine, glutamine at position 386 of SEQ ID NO: 1 is substituted with arginine, and asparagine at position 487 of SEQ ID NO: 1 is substituted with aspartic acid; (B) the glycine at position 390 of SEQ ID NO: 1 is substituted with serine, the tyrosine at position 342 of SEQ ID NO: 1 is substituted with cysteine, and the serine at position 476 of SEQ ID NO: 1 is substituted with arginine; (C) glycine at position 390 of sequence number 1 is substituted with serine, isoleucine at position 319 of sequence number 1 is substituted with phenylalanine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, and serine at position 476 of sequence number 1 is substituted with arginine; (D) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (E) glycine at position 390 of sequence number 1 is substituted with serine, isoleucine at position 319 of sequence number 1 is substituted with phenylalanine, lysine at position 323 of sequence number 1 is substituted with glutamic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, and serine at position 476 of sequence number 1 is substituted with arginine; (F) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (F1) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the valine at position 317 of sequence number 1 is substituted with aspartic acid; (F2) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and lysine at position 371 of sequence number 1 is substituted with glutamic acid; (F3) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and lysine at position 371 of sequence number 1 is substituted with asparagine; (F4) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and leucine at position 376 of sequence number 1 is substituted with proline; (F5) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and glutamic acid at position 378 of sequence number 1 is substituted with glycine; (F6) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and glycine at position 392 of sequence number 1 is substituted with cysteine; (F7) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, threonine at position 320 of sequence number 1 is substituted with alanine, and valine at position 381 of sequence number 1 is substituted with aspartic acid; (F8) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, valine at position 326 of sequence number 1 is substituted with glutamic acid, and asparagine at position 329 of sequence number 1 is substituted with histidine; (F9) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, valine at position 326 of sequence number 1 is substituted with alanine, and lysine at position 362 of sequence number 1 is substituted with glutamic acid; (F10) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 326 of sequence number 1 is substituted with glutamic acid, and the phenylalanine at position 379 of sequence number 1 is substituted with serine; (F11) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 332 of sequence number 1 is substituted with alanine, and the lysine at position 371 of sequence number 1 is substituted with glutamic acid; (F12) glycine at position 390 of sequence number 1 is substituted with serine, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, leucine at position 376 of sequence number 1 is substituted with proline, and asparagine at position 492 of sequence number 1 is substituted with aspartic acid; (F13) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamine at position 318 of sequence number 1 is substituted with proline, the phenylalanine at position 379 of sequence number 1 is substituted with tyrosine, and the glutamic acid at position 401 of sequence number 1 is substituted with valine; (F14) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the asparagine at position 324 of sequence number 1 is substituted with aspartic acid, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, and the valine at position 499 of sequence number 1 is substituted with glutamic acid; (F15) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 326 of sequence number 1 is substituted with glutamic acid, the asparagine at position 329 of sequence number 1 is substituted with histidine, and the glutamic acid at position 378 of sequence number 1 is substituted with valine; (F16) the glycine at position 390 of sequence number 1 is substituted with serine, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the leucine at position 328 of sequence number 1 is substituted with proline, the lysine at position 362 of sequence number 1 is substituted with asparagine, the threonine at position 397 of sequence number 1 is substituted with serine, and the arginine at position 406 of sequence number 1 is substituted with histidine; (G) glycine at position 390 of sequence number 1 is substituted with serine, asparagine at position 324 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (H) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (I) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, asparagine at position 324 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (J) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (J1) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and glutamic acid at position 340 of sequence number 1 is substituted with valine; (J2) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and tyrosine at position 344 of sequence number 1 is substituted with phenylalanine; (J3) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and arginine at position 353 of sequence number 1 is substituted with cysteine; (J4) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and tyrosine at position 355 of sequence number 1 is substituted with cysteine; (J5) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and serine at position 356 of sequence number 1 is substituted with cysteine; (J6) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and methionine at position 359 of sequence number 1 is substituted with leucine; (J7) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and glutamic acid at position 360 of sequence number 1 is substituted with lysine; (J8) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and glutamic acid at position 360 of sequence number 1 is substituted with valine; (J9) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glycine, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, and asparagine at position 487 of sequence number 1 is substituted with aspartic acid; (J10) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the serine at position 364 of sequence number 1 is substituted with leucine; (J11) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the isoleucine at position 366 of sequence number 1 is substituted with threonine; (J12) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the leucine at position 372 of sequence number 1 is substituted with proline; (J13) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the leucine at position 372 of sequence number 1 is substituted with glutamine; (J14) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the threonine at position 373 of sequence number 1 is substituted with alanine; (J15) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the leucine at position 376 of sequence number 1 is substituted with proline; (J16) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the glutamic acid at position 378 of sequence number 1 is substituted with glycine; (J17) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the phenylalanine at position 379 of sequence number 1 is substituted with serine; (J18) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the lysine at position 380 of sequence number 1 is substituted with glutamic acid; (J19) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the valine at position 381 of sequence number 1 is substituted with alanine; (J20) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the glutamine at position 386 of sequence number 1 is substituted with arginine; (J21) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the tyrosine at position 393 of sequence number 1 is substituted with cysteine; (J22) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the glutamine at position 441 of sequence number 1 is substituted with arginine; (J23) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the histidine at position 443 of sequence number 1 is substituted with leucine; (J24) glycine at position 390 of sequence number 1 is substituted with serine, valine at position 317 of sequence number 1 is substituted with aspartic acid, tyrosine at position 342 of sequence number 1 is substituted with cysteine, lysine at position 362 of sequence number 1 is substituted with glutamic acid, lysine at position 371 of sequence number 1 is substituted with asparagine, lysine at position 399 of sequence number 1 is substituted with glutamic acid, serine at position 476 of sequence number 1 is substituted with arginine, asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and lysine at position 448 of sequence number 1 is substituted with glutamic acid; (J25) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the aspartic acid at position 483 of sequence number 1 is substituted with asparagine; (J26) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the serine at position 312 of sequence number 1 is substituted with proline, and the proline at position 374 of sequence number 1 is substituted with leucine; (J27) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the alanine at position 313 of sequence number 1 is substituted with serine, and the glutamic acid at position 378 of sequence number 1 is substituted with glycine; (J28) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the lysine at position 323 of sequence number 1 is substituted with arginine, and the glutamic acid at position 384 of sequence number 1 is substituted with valine; (J29) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the asparagine at position 324 of sequence number 1 is substituted with serine, and the glycine at position 357 of sequence number 1 is substituted with cysteine; (J30) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamine at position 327 of sequence number 1 is substituted with histidine, and the glutamic acid at position 378 of sequence number 1 is substituted with valine; (J31) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with aspartic acid, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, and the glutamine at position 327 of sequence number 1 is substituted with leucine; (J32) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the asparagine at position 329 of sequence number 1 is substituted with isoleucine, and the valine at position 499 of sequence number 1 is substituted with isoleucine; (J33) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamic acid at position 335 of sequence number 1 is substituted with glycine, and the glutamine at position 386 of sequence number 1 is substituted with arginine; (J34) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamic acid at position 335 of sequence number 1 is substituted with valine, and the threonine at position 343 of sequence number 1 is substituted with serine; (J35) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the threonine at position 341 of sequence number 1 is substituted with proline, and the phenylalanine at position 379 of sequence number 1 is substituted with serine; (J36) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the leucine at position 369 of sequence number 1 is substituted with glutamine, and the proline at position 374 of sequence number 1 is substituted with leucine; (J37) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the leucine at position 372 of sequence number 1 is substituted with proline, and the valine at position 396 of sequence number 1 is substituted with alanine; (J38) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamic acid at position 378 of sequence number 1 is substituted with glycine, and the arginine at position 403 of sequence number 1 is substituted with histidine; (J39) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 381 of sequence number 1 is substituted with alanine, and the isoleucine at position 382 of sequence number 1 is substituted with valine; (J40) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 383 of sequence number 1 is substituted with alanine, and the glutamine at position 415 of sequence number 1 is substituted with arginine; (J41) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the tryptophan at position 346 of sequence number 1 is substituted with cysteine, the arginine at position 353 of sequence number 1 is substituted with cysteine, and the histidine at position 389 of sequence number 1 is substituted with arginine; (J42) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the leucine at position 372 of sequence number 1 is substituted with glutamine, the leucine at position 376 of sequence number 1 is substituted with proline, and the valine at position 394 of sequence number 1 is substituted with aspartic acid; (J43) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the phenylalanine at position 379 of sequence number 1 is substituted with cysteine, the glutamine at position 432 of sequence number 1 is substituted with leucine, and the serine at position 488 of sequence number 1 is substituted with leucine; (J44) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the glutamic acid at position 384 of sequence number 1 is substituted with valine, the glutamine at position 432 of sequence number 1 is substituted with arginine, and the isoleucine at position 456 of sequence number 1 is substituted with valine; (J45) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 394 of sequence number 1 is substituted with isoleucine, the aspartic acid at position 395 of sequence number 1 is substituted with serine, and the threonine at position 426 of sequence number 1 is substituted with alanine; (J46) the glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with cysteine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, the asparagine at position 487 of sequence number 1 is substituted with aspartic acid, the valine at position 396 of sequence number 1 is substituted with alanine, the glutamine at position 441 of sequence number 1 is substituted with arginine, and the lysine at position 448 of sequence number 1 is substituted with glutamic acid; (K) The glycine at position 390 of sequence number 1 is substituted with serine, the valine at position 317 of sequence number 1 is substituted with aspartic acid, the tyrosine at position 342 of sequence number 1 is substituted with serine, the lysine at position 362 of sequence number 1 is substituted with glutamic acid, the lysine at position 371 of sequence number 1 is substituted with asparagine, the valine at position 381 of sequence number 1 is substituted with alanine, the isoleucine at position 382 of sequence number 1 is substituted with valine, the lysine at position 399 of sequence number 1 is substituted with glutamic acid, the serine at position 476 of sequence number 1 is substituted with arginine, and the asparagine at position 487 of sequence number 1 is substituted with aspartic acid.
2. The AAV-binding protein according to claim 1, wherein the sequence is an amino acid sequence from serine at position 25 to aspartic acid at position 213 in the amino acid sequence described in SEQ ID NO:
76.
3. A polynucleotide encoding the AAV binding protein of claim 1 or 2. An expression vector comprising the polynucleotide according to claim 3.
5. A transformant obtained by transforming a host with the expression vector according to claim 4.
6. The transformant according to claim 5, in, The host is Escherichia coli.
7. A method for producing an AAV binding protein, wherein include: A step of expressing an AAV-binding protein by culturing the transformant according to claim 5 or 6; and a step of recovering the expressed AAV-binding protein from the obtained culture.
8. An AAV adsorbent comprising an insoluble carrier, and the AAV-binding protein according to claim 1 or 2 immobilized on the carrier.
9. A column comprising the AAV adsorbent according to claim 8.
10. A method for purifying AAV, wherein include: A step of adding a solution containing AAV to the column according to claim 9 to allow the adsorbent to adsorb the AAV; And, a step of eluting the AAV adsorbed to the adsorbent using an elution solution.
